Document:

EX-10.3

 Exhibit 10.3 

Execution Version 

SIXTH AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

by and among 

NEURONETICS, INC. 
 and

 THE STOCKHOLDERS LISTED HEREIN 

Dated as of June 1, 2017 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
	
	TABLE OF CONTENTS	 
			
	1.	  	VOTING AGREEMENT	  	 	3	 
				
		  	1.1.	  	Agreement with Respect to Voting	  	 	3	 
				
		  	1.2.	  	Board of Directors	  	 	3	 
				
		  	1.3.	  	No “Bad Actor” Designees	  	 	4	 
			
	2.	  	RESTRICTIONS ON ISSUANCE AND TRANSFER OF SECURITIES	  	 	5	 
				
		  	2.1.	  	Certain Definitions	  	 	5	 
				
		  	2.2.	  	General	  	 	8	 
				
		  	2.3.	  	Prohibited Transfers Void	  	 	8	 
			
	3.	  	FIRST-REFUSAL AND CO-SALE RIGHTS AS TO STOCK TRANSFERS	  	 	8	 
				
		  	3.1.	  	Transfer Notice	  	 	8	 
				
		  	3.2.	  	Company’s and Preferred Stockholders’ Options	  	 	8	 
			
	4.	  	DRAG-ALONG RIGHT OF SECURITIES	  	 	12	 
				
		  	4.1.	  	Definitions Used in This Section	  	 	12	 
				
		  	4.2.	  	Actions to be Taken	  	 	13	 
			
	5.	  	PROCEDURES FOR INVOLUNTARY TRANSFERS	  	 	17	 
				
		  	5.1.	  	Transfers by Operation of Law	  	 	17	 
				
		  	5.2.	  	Determination of Fair Market Value	  	 	18	 
			
	6.	  	RESTRICTIVE LEGENDS	  	 	18	 
			
	7.	  	TERMINATION OF AGREEMENT	  	 	18	 
			
	8.	  	ADDITIONAL STOCKHOLDERS	  	 	18	 
			
	9.	  	“BAD ACTOR” MATTERS	  	 	19	 
				
		  	9.1.	  	Representation	  	 	19	 
				
		  	9.2.	  	Covenant	  	 	19	 
			
	10.	  	MISCELLANEOUS PROVISIONS	  	 	19	 
				
		  	10.1.	  	Amendments, Consents, Waivers, Etc.	  	 	19	 
				
		  	10.2.	  	Notices	  	 	21	 
				
		  	10.3.	  	Pepper Hamilton Representation	  	 	23	 
				
		  	10.4.	  	Counterparts	  	 	24	 
				
		  	10.5.	  	Captions	  	 	24	 

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	  	 	  	 	  	Page	 
				
		  	10.6.	  	Binding Effect and Benefits	  	 	24	 
				
		  	10.7.	  	Construction	  	 	25	 
				
		  	10.8.	  	Entire Agreement	  	 	25	 
				
		  	10.9.	  	Severability	  	 	25	 
				
		  	10.10.	  	Equitable Relief	  	 	25	 
				
		  	10.11.	  	Governing Law	  	 	25	 
				
		  	10.12.	  	Assignment of Rights	  	 	25	 
				
		  	10.13.	  	Jurisdiction	  	 	26	 
			
	11.	  	AGGREGATION OF STOCK	  	 	26	 
			
	12.	  	REMEDIES	  	 	26	 
			
	13.	  	OWNERSHIP	  	 	26	 
			
	14.	  	SPOUSAL CONSENT	  	 	26	 

  
 -ii- 

 SIXTH AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

This Sixth Amended and Restated Stockholders’ Agreement (this “Agreement”), dated as of June 1, 2017, is by and
among (i) Neuronetics, Inc., a Delaware corporation (the “Company”); (ii) the persons listed as owners of the Company’s Common Stock listed on the Schedule of Common Stockholders attached hereto (the
“Common Stockholders”); (iii) the persons listed as owners of Series A-1 Preferred Stock, listed on the Schedule of Series A-1 Stockholders
attached hereto (the “Series A-1 Holders”); (iv) the persons listed as owners of Series A-2 Preferred Stock, listed on the Schedule of A-2 Stockholders attached hereto (the “Series A-2 Holders”); (v) the persons listed as owners of Series B Preferred Stock, listed on the Schedule
of Series B Stockholders attached hereto (the “Series B Holders”); (vi) the persons listed as owners of Series C Preferred Stock, listed on the Schedule of Series C Stockholders attached hereto (the
“Series C Holders”); (vii) the persons listed as owners of Series D Preferred Stock, listed on the Schedule of Series D Stockholders attached hereto (the “Series D Holders”); (viii) the persons listed as
owners of Series E Preferred Stock, listed on the Schedule of Series E Stockholders attached hereto (the “Series E Holders”); (ix) the persons listed as owners of Series F Preferred Stock, listed on the Schedule of Series
F Stockholders attached hereto (the “Series F Holders”); (x) the persons listed as owners of Series G Preferred Stock, listed on the Schedule of Series G Stockholders attached hereto (the “Series G
Holders”); (xi) the Key Officers listed on the Schedule of Key Officers attached hereto; and (xii) each person or entity that subsequently becomes a party to this Agreement by signing an Instrument of Adherence pursuant to
Section 8 hereof (the “Additional Stockholders,” and, together with the Common Stockholders, Series A-1 Holders, Series A-2 Holders, Series B
Holders, Series C Holders, Series D Holders, Series E Holders, Series F Holders, the Series G Holders and Key Officers, collectively, the “Stockholders”). 

WHEREAS, the Series A-1 Holders own of record an aggregate of 4,800,000 shares of Series A-1 Preferred Stock; 
 WHEREAS, the Series A-2 Holders own of
record an aggregate of 25,384,615 shares of Series A-2 Preferred Stock, which were issued pursuant to the terms of that certain Series A-2 Preferred Stock Purchase
Agreement dated as of April 3, 2003 (the “Series A-2 Purchase Agreement”); 

WHEREAS, the Series B Holders own of record an aggregate of 17,000,000 shares of Series B Preferred Stock, which were issued pursuant to the
terms of that certain Series B Preferred Stock Purchase Agreement dated as of March 4, 2005 (the “Series B Purchase Agreement”); 

WHEREAS, the Series C Holders own of record an aggregate of 20,958,084 shares of Series C Preferred Stock, which were issued pursuant to the
terms of that certain Series C Preferred Stock Purchase Agreement dated as of August 2, 2006 (the “Series C Purchase Agreement”); 

  
 -1- 

 WHEREAS, the Series D Holders own of record an aggregate of 49,426,229 shares of Series D
Preferred Stock, which were issued pursuant to the terms of that certain Series D Preferred Stock Purchase Agreement dated as of August 20, 2009 (the “Series D Purchase Agreement”); 

WHEREAS, the Series E Holders own of record an aggregate of 44,470,799 shares of Series E Preferred Stock, which were issued pursuant to the
terms of that certain Series E Preferred Stock Purchase Agreement dated as of May 13, 2011 (the “Series E Purchase Agreement”); 

WHEREAS, the Series F Holders own of record an aggregate of 102,334,194 shares of Series F Preferred Stock, which were issued pursuant to the
terms of that certain Series F Preferred Stock Purchase Agreement dated as of April 24, 2015 (the “Series F Purchase Agreement”); 

WHEREAS, in connection with the purchase of the Series F Preferred Stock, the Company, the Series A-1
Holders, the Series A-2 Holders, the Series B Holders, the Series C Holders, the Series D Holders, the Series E Holders, the Series F Holders and the Common Stockholders entered into that certain Fifth Amended
and Restated Stockholders’ Agreement dated as of April 24, 2015 (as amended from time to time thereafter, the “Prior Agreement”); 

WHEREAS, the Company and the Series G Holders desire to enter into a Series G Preferred Stock Purchase Agreement (the “Series G
Purchase Agreement”), to be dated as of or about the date hereof, pursuant to which the Company will issue and sell shares of Series G Preferred Stock to the Series G Holders, subject to the terms and conditions set forth in the Series G
Purchase Agreement; 
 WHEREAS, but for the execution and delivery of this Agreement by the Company, the Stockholders and the Key Officers,
the Series G Holders would not be willing to enter into the Series G Purchase Agreement or to consummate the transactions thereby contemplated, which transactions will benefit the Company, such Stockholders and Key Officers; and 

WHEREAS, in connection with the sale and issuance of the Series G Preferred Stock, the Stockholders and the Company wish to set forth certain
agreements regarding their future relationships and their rights and obligations with respect to the Shares (as this term is defined below) and to amend and restate the Prior Agreement in its entirety as set forth herein. 

  
 - 2 - 

 NOW, THEREFORE, in order to induce the Series G Holders to consummate the transactions
contemplated by the Series G Purchase Agreement, the parties hereby agree as follows: 
  

	1.	VOTING AGREEMENT. 

 1.1. Agreement with Respect to Voting. For so long as this Agreement remains
in effect, each Stockholder shall vote (whether at a meeting or by written consent in lieu of a meeting) any and all shares of the Company’s capital stock held by him, her or it from time to time (to the extent such shares may have the right to
vote with respect to such matters), to maintain the size and membership of the Company’s board of directors (the “Board of Directors”), and to cause the Company to act, or abstain from acting, in accordance with all of the
provisions of this Agreement. The Company will not recognize or give effect to any vote or consent of any Stockholder in violation of this Agreement. 

1.2. Board of Directors. The Stockholders agree to vote all shares of the Company’s Common Stock, Preferred Stock and any other class of voting
security of the Company now or hereafter owned or controlled by them (the “Shares”), to the extent such Shares may have the right to vote with respect to such matters, and otherwise to use their respective best efforts as
stockholders of the Company, to (i) fix the authorized number of directors constituting the whole Board of Directors at up to nine (9), and (ii) elect as directors of the Company on the date hereof and in any subsequent election of
directors the following persons: (a) as the Series A-2 Directors (as defined in the Charter), up to two (2) persons nominated by the Majority Series A-2
Holders, voting together as a single class, one of whom shall at all times be the nominee of Investor Growth Capital Limited or its successors and who shall initially after the date hereof be Stephen Campe, and one (1) of whom may be the
nominee of ONSET IV, L.P. or its successors, provided that this seat shall initially after the date hereof be left vacant; (b) as the Series B Director (as defined in the Charter), one (1) person nominated by Three Arch Partners, who shall
initially after the date hereof be Wilfred Jaeger; (c) as the Series C Director (as defined in the Charter), up to one (1) person nominated by QPIV, LLC, provided that this seat shall initially after the date hereof be left vacant;
(d) as the Series D Director (as defined in the Charter), one (1) person nominated by New Leaf, who shall initially after the date hereof be Ronald Hunt; (e) as the Series E Director (as defined in the Charter), one (1) person
nominated by Polaris, who shall initially after the date hereof be Kevin Bitterman; and (f) as the Remaining Directors (as defined in the Charter), up to three (3) persons nominated by the Stockholders holding at least a majority of the
outstanding shares of Common Stock and Preferred Stock, voting together as a single class on an as-converted to Common Stock basis (the “Majority Holders”); provided, that one (1) of the
Remaining Directors shall be the Chief Executive Officer of the Company as appointed by the Board of Directors from time to time (the “CEO Director”) and at least one (1) of such Remaining Directors shall be an independent
director (who shall initially after the date hereof be Brian Farley), as determined by the remaining members of the Board of Directors (x) who is not an employee of the Company or any Preferred Stockholder owning Preferred Stock constituting
greater than 0.5% of the fully-diluted issued and outstanding Common Stock (after giving effect to the conversion and/or exercise of all then outstanding Derivative Securities) and (y) who has experience in the Company’s industry. 

  
 - 3 - 

 In the event of termination of employment, resignation, death, removal or disqualification of the Company’s
Chief Executive Officer, the Board of Directors shall appoint a new Chief Executive Officer (who may be, for avoidance of doubt, an interim chief executive officer). Upon such appointment, the Majority Holders shall nominate such new Chief Executive
Officer as the CEO Director and if necessary, remove the former Chief Executive Officer as the CEO Director. Other than with respect to the CEO Director, the power to nominate a director pursuant to this Section 1.2 includes the exclusive power
to recommend the removal of such director for any reason or no reason (subject to the bylaws of the Company as in effect from time to time and any requirements of applicable law). If any person or group specified in this Section 1.2 as having
the right to nominate a director (a “Nominator”) gives written notice to the other Stockholders of a desire to remove a director nominated by the Nominator, the other Stockholders will vote all of their Shares in favor of removing
that director. If for any reason any director nominated by a Nominator ceases to hold office, the Nominator will have the right to nominate another individual to fill the vacancy so created for the unexpired term of office of such former director,
and the other Stockholders will vote all of their Shares in favor of electing the individual so nominated to fill such vacancy. 
 The Board of Directors
shall continue to maintain an audit committee consisting of at least two (2) directors, and such committee shall be charged with the customary responsibilities of an audit committee. The Board of Directors shall continue to maintain a
compensation committee consisting of at least three (3) directors, including the Series E Director, and such committee shall continue to be charged with the customary responsibilities of a compensation committee, including responsibility for
approval of base salaries, incentive bonuses and grants of options, restricted stock awards and warrants for officers and other key employees of the Company. 

There will not be any other committee (including, without limitation, any executive committee) of the Board of Directors unless such committee is specifically
approved by the Board of Directors, including the Super Board Approval, and one (1) of the Series A-2 Directors, the Series B Director, the Series C Director, the Series D Director or the Series E
Director is the Chairman of each such committee and each of the remaining members of the Board of Directors has the option to be a member of each such committee. Members of the Board of Directors who are not members of a particular committee shall
have the right to attend any meeting of such committee. 
 1.3. No “Bad Actor” Designees. Each Person with the right to designate or
participate in the designation of a director as specified above hereby represents and warrants to the Company that, to such Person’s knowledge, none of the “bad actor” disqualifying events described in Rule 506(d)(1)(i)-(viii)
promulgated under the Securities Act of 1933, as amended (the “Securities Act”) (each, a “Disqualification Event”), is applicable to such Person’s initial designee named above except, if applicable, for a
Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable. Any director designee to whom any Disqualification Event is applicable, except for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or
(d)(3) is applicable, is hereinafter referred to as a “Disqualified Designee”. Each Person with the right to designate or participate in the designation of a director as specified above hereby covenants and agrees (A) not to
designate or participate in the designation of any director designee who, to such Person’s knowledge, is a Disqualified Designee and (B) that in the event such Person becomes aware that 

  
 - 4 - 

 
any individual previously designated by any such Person is or has become a Disqualified Designee, such Person shall as promptly as practicable take such actions as are necessary to remove such
Disqualified Designee from the Board and designate a replacement designee who is not a Disqualified Designee. 
  

	2.	RESTRICTIONS ON ISSUANCE AND TRANSFER OF SECURITIES. 

 2.1. Certain Definitions. As used in this
Agreement: 
 (a) “Affiliate Stockholder” of any Stockholder or permitted assignee means any general or limited partner or
retired partner of any such person that is a partnership, any member or retired member of any such person that is a limited liability company, or any person or entity that, directly or indirectly, through one or more intermediaries, controls, or is
controlled by, or is under common control with, such Stockholder or permitted assignee. 
 (b) “Acquisition” shall have the
meaning assigned to such term in the Charter. 
 (c) “Change of Control” means a transaction or series of related
transactions in which a person, or a group of related persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company. 

(d) “Charter” means the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended and in effect
from time to time. 
 (e) “CHV” means CHV IV, L.P. 

(f) “Common Stock” means the Common Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in
the Charter. 
 (g) “Derivative Securities” means (i) all shares of stock and other securities that are convertible
into or exchangeable for shares of Common Stock, including shares of Preferred Stock, and (ii) all options, warrants and other rights to acquire shares of Common Stock or securities convertible into or exchangeable for shares of Common Stock.

 (h) “Key Officer” shall mean the Chief Executive Officer and each Vice President (or higher level) who reports directly
to the Chief Executive Officer of the Company, for so long as such officer is providing services to the Company as an officer, employee or consultant, and thereafter. The Key Officers on the date of this Agreement are listed on the Schedule of
Key Officers attached hereto. For avoidance of doubt, once an individual is a Key Officer, such individual shall remain a “Key Officer” for purposes of this Agreement even if such individual ceases to provide services to the Company).

 (i) “Majority Series A-2 Holders” means, collectively, the Stockholders holding
at least a majority of the then-outstanding shares of Series A-2 Preferred Stock. 

  
 - 5 - 

 (j) “Majority Series B Holders” means, collectively, the Stockholders holding at
least a majority of the then-outstanding shares of Series B Preferred Stock. 
 (k) “Majority Series C Holders” means,
collectively, the Stockholders holding at least a majority of the then-outstanding shares of Series C Preferred Stock. 
 (l)
“Majority Series G Holders” means, collectively, the Stockholders holding at least a majority of the then-outstanding shares of Series G Preferred Stock. 

(m) “One Percent Common Stockholder” means any Common Stockholder who holds issued and outstanding shares of Common Stock
(whether acquired by exercise of options or otherwise) representing at least one percent (1.0%) of the issued and outstanding Common Stock of the Company (for purposes of this calculation, assuming the conversion and/or exercise of all then
outstanding Derivative Securities). For avoidance of doubt, once a Common Stockholder is a One Percent Common Stockholder, such Common Stockholder shall remain a “One Percent Common Stockholder” for purposes of this Agreement even if the
Company issues additional shares of capital stock (including any Derivative Securities). 
 (n) “Permitted Transferee(s)”
means, with respect to any Restricted Holder, such Restricted Holder’s Family Members (as defined below) or any transferee by will, descent, distribution or gift. “Family Members” means, as applied to any individual, whether by
blood or adoption, his or her spouse, his or her and his or her spouse’s lineal ancestors and descendants and their respective spouses, any trust created for the benefit of any such person(s), and each custodian of property of any such
person(s), and/or the estate of any such person(s). 
 (o) “Person” (regardless of whether capitalized) means any natural
person, entity or association, including any corporation, partnership, limited liability company, government (or agency or subdivision thereof), trust, joint venture or proprietorship. 

(p) “Polaris” means Polaris Venture Partners V, L.P., Polaris Venture Partners Entrepreneurs’ Fund V, L.P., Polaris
Venture Partners Special Founders’ Fund V, L.P. and Polaris Venture Partners Founders’ Fund V, L.P. 
 (q) “Preferred
Stock” means the Series A-1 Preferred Stock, the Series A-2 Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred
Stock, the Series E Preferred Stock, the Series F Preferred Stock and the Series G Preferred Stock. 
 (r) “Preferred
Stockholders” means the Stockholders holding Preferred Stock. 
 (s) “Qualified Public Offering” shall have the
meaning assigned to such term in the Charter. 
 (t) “Required Series D Holders” means, collectively, the Stockholders
holding at least sixty-five percent (65%) of the then-outstanding shares of Series D Preferred Stock. 

  
 - 6 - 

 (u) “Required Series E Holders” means, collectively, the Stockholders holding at
least sixty percent (60%) of the then-outstanding shares of Series E Preferred Stock. 
 (v) “Required Series F Holders”
means, collectively, the Stockholders holding at least seventy-five percent (75%) of the then-outstanding shares of Series F Preferred Stock. 

(w) “Required Series G Holders” means, collectively, the Stockholders holding at least fifty-five percent (55)% of the
then-outstanding shares of Series G Preferred Stock. 
 (x) “Restricted Holder” means each of the Key Officers, the Common
Stockholders and the Series A-1 Holders. 
 (y) “Series
A-1 Preferred Stock” means the Series A-1 Convertible Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the
Charter. 
 (z) “Series A-2 Preferred Stock” means the Series A-2 Convertible Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the Charter. 

(aa) “Series B Preferred Stock” means the Series B Convertible Preferred Stock, $0.01 par value per share, of the Company,
the terms of which are as set forth in the Charter. 
 (bb) “Series C Preferred Stock” means the Series C Convertible
Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the Charter. 
 (cc) “Series D
Preferred Stock” means the Series D Convertible Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the Charter. 

(dd) “Series E Preferred Stock” means the Series E Convertible Preferred Stock, $0.01 par value per share, of the Company,
the terms of which are as set forth in the Charter. 
 (ee) “Series F Preferred Stock” means the Series F Convertible
Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the Charter. 
 (ff) “Series G
Preferred Stock” means the Series G Convertible Preferred Stock, $0.01 par value per share, of the Company, the terms of which are as set forth in the Charter. 

(gg) “Super Board Approval” shall have the meaning assigned to such term in the Charter. 

(hh) “Transfer” (whether used as a noun or a verb) refers to any sale, pledge, assignment, encumbrance, gift or other
disposition or transfer of shares of capital stock or other equity securities of the Company (as used in this Agreement, the terms “equity security” and “equity securities” include, without limitation, options,
warrants and other rights to acquire shares of the Company’s capital stock, and securities and other instruments that are convertible into or exchangeable for shares of the Company’s capital stock, and/or any legal or beneficial interest
in any of the foregoing), or any legal or beneficial interest therein, including any tender 

  
 - 7 - 

 
or transfer in connection with any merger, recapitalization, reclassification, or tender or exchange offer (for all or any part of the Company’s equity securities), whether or not the person
making any such transfer votes for or against any transaction involving any such Transfer. 
 2.2. General. No Restricted Holder will
make any Transfer, or enter into, consent to or vote in favor of any transaction that would result in any Transfer by him, her or it, unless all the provisions of this Agreement that are applicable to such Transfer have been complied with; provided,
that a Restricted Holder may make a Transfer to any Permitted Transferee, if prior to such Transfer such Permitted Transferee agrees in a writing delivered to the Company and each of the Preferred Stockholders (naming the Company and such Preferred
Stockholders as intended third-party beneficiaries) to be bound by all of the terms of this Agreement that are applicable to Restricted Holders and; provided, further, that, if the transferee is an individual, such Transfer will not be permitted
unless such Transfer is effected pursuant to and in conformity with any applicable state securities or blue sky laws and, if reasonably requested by the Company, such Restricted Holder shall have obtained and delivered to the Company a written legal
opinion of counsel (reasonably satisfactory to the Company as to such counsel and as to the substance of such opinion) to the effect that any such proposed Transfer does not violate the registration provisions of the Securities Act of 1933, as
amended, and any applicable state securities or blue sky laws (any such Transfer, a “Permitted Transfer”). 
 2.3. Prohibited Transfers
Void. Any attempted Transfer in violation of the terms of this Agreement will be ineffective to vest in any purported transferee any right, title or interest in or to the securities purported to be Transferred, and the Company will not
recognize any such purported transferee as the holder or owner of such securities for any purpose, including, without limitation, for purposes of exercising voting rights or rights to receive dividends or other distributions in respect of such
securities. 
 3. FIRST-REFUSAL AND CO-SALE RIGHTS AS TO STOCK TRANSFERS. 

3.1. Transfer Notice. At least 30 days prior to any proposed Transfer (other than a Permitted Transfer) by a Restricted Holder, such Restricted
Holder (the “Transferring Stockholder”) will give notice (the “Transfer Notice”) to the Company and each of the Preferred Stockholders in accordance with Section 10.2 hereof, setting forth (i) the number
and class of equity securities proposed to be sold by the Transferring Stockholder (the “Offered Securities”), (ii) the anticipated date of the proposed Transfer (the “Transfer Date”) and the names and
addresses of the proposed transferees, and (iii) the material terms of the proposed Transfer, including the cash and/or other consideration to be received in respect of such Transfer. 

3.2. Company’s and Preferred Stockholders’ Options. Upon the giving of any Transfer Notice, then, subject to all of the provisions of
this Section 3.2, the Company and the Preferred Stockholders will have certain rights and options, as follows: 
 (a) Rights of
First Refusal. The Company and the Preferred Stockholders will have the option, but not the obligation, to purchase some or all of the Offered Securities on the same terms as are specified in the Transfer Notice, including any deferred payment
terms; provided, 

  
 - 8 - 

 
that the Company and the Preferred Stockholders will have the right to substitute cash in the amount of the fair market value of any non-cash consideration
proposed to be received from the proposed transferees. Within fifteen (15) days after the effective date of the Transfer Notice, the Company and each of the Preferred Stockholders will give written notice to the Transferring Stockholder stating
whether he, she or it elects to exercise such option, and if so, how many of the Offered Securities he, she or it elects to purchase (the “Subscription Amount”). Failure by the Company or any Preferred Stockholder to give such
notice within such time period will be deemed an election by him, her or it not to exercise his, her or its option. If the aggregate number of securities for which the Company and the Preferred Stockholders exercise such options exceeds the total
number of Offered Securities, then the Company will be entitled to purchase all of the Offered Securities as to which it has exercised its option if such number does not exceed the total number of Offered Securities and otherwise will be entitled to
purchase all of the Offered Securities, and each Preferred Stockholder who has exercised his, her or its option will be entitled to purchase a number of the remaining Offered Securities (the “Basic Amount”), if any, equal to the
proportion that the number of shares of Common Stock held by such Preferred Stockholder bears to the number of shares of Common Stock held by all such Preferred Stockholders (for this purpose, including shares of Common Stock issuable upon exercise,
conversion or exchange of shares of Preferred Stock and other Derivative Securities held by such Preferred Stockholder). If the total number of Offered Securities exceeds the aggregate number of securities for which the Company and the Preferred
Stockholders exercise such options (such excess being referred to herein as the “Available Overallotment Amount”), then each Preferred Stockholder whose Subscription Amount exceeds such Preferred Stockholder’s Basic Amount (the
difference between the Preferred Stockholder’s Subscription Amount and the Preferred Stockholder’s Basic Amount being referred to herein as such Preferred Stockholder’s “Overallotment Amount”) shall be entitled to
purchase such Preferred Stockholder’s Overallotment Amount; provided, that should the Overallotment Amounts subscribed for exceed the Available Overallotment Amount, then each Preferred Stockholder’s Overallotment Amount shall be
reduced such that the Available Overallotment Amount is allocated among such Preferred Stockholders pro rata, based on their respective Basic Amounts (but not in excess of their respective Overallotment Amounts), with any Available
Overallotment Amount remaining after such reallocation being further re-allocated in the same manner until the entire Available Overallotment Amount has been so allocated. The closing of the purchase and sale
of the Offered Securities will take place as soon as is reasonably practicable at such date (but in any event within ten (10) days after the expiration of the fifteen (15) day period referred to above) (or the next business day if such
tenth (10th) day is not a business day), time and place as the Company and the Preferred Stockholders exercising their purchase options hereunder may reasonably determine. If the Company and the
Preferred Stockholders do not elect to purchase some or all of the Offered Securities hereunder, then subject to the provisions of Section 3.2(b) hereof, the Transferring Stockholder will thereafter be free for a period of ninety (90) days
after the date of the Transfer Notice to consummate, with respect to the Offered Securities not purchased, the Transfer described in the Transfer Notice to the transferee(s) specified therein, at the price and on the other terms set forth therein;
provided, that such transferee(s) first executes and delivers to the Company a written agreement to be bound by all of the provisions of this Agreement applicable to Restricted Holders and naming the Company and the Preferred

  
 - 9 - 

 
Stockholders as intended third-party beneficiaries of such agreement. If such Transfer is not consummated within such ninety (90) day period, however, the Transferring Stockholder will not
Transfer any of the Offered Securities without again complying with all of the provisions of this Section 3. 
 (b) Co-Sale Rights. Upon receipt of a Transfer Notice, each of the Preferred Stockholders (other than any of them who elect to purchase any of the Offered Securities pursuant to Section 3.2(a) hereof), may
elect to participate in the contemplated Transfer by delivering written notice to the Transferring Stockholder within fifteen (15) days after the effective date of such Transfer Notice. Each of the Preferred Stockholders so electing will be
entitled to sell in the contemplated Transfer, at the same price and on the same terms as specified in the Transfer Notice, a number of shares of Common Stock equal to (and not less than) the product of (i) the quotient determined by dividing
(A) the number of shares of Common Stock held by such Preferred Stockholder (for this purpose, including shares of Common Stock issuable upon exercise, conversion or exchange of shares of Preferred Stock and other Derivative Securities held by
such Preferred Stockholder), by (B) the aggregate number of shares of Common Stock held by the Transferring Stockholder and all such Preferred Stockholders (for this purpose, including shares of Common Stock issuable upon exercise, conversion,
or exchange of shares of Preferred Stock and other Derivative Securities held by the Transferring Stockholder and all such Preferred Stockholders), and (ii) after giving effect to Section 3.2(a), the remaining Offered Securities to be sold
in the contemplated Transfer. The Transferring Stockholder will be entitled to sell in the contemplated Transfer the balance of the equity securities proposed to be so sold. The Transferring Stockholder will use his, her or its best efforts to
obtain the agreement of the prospective transferee(s) to allow the participation of the Preferred Stockholders in any contemplated Transfer and will not Transfer any equity securities to such prospective transferee(s) unless (y) such
prospective transferee(s) allows the participation of the Preferred Stockholders on the terms specified herein or (z) simultaneously with such sale, the Transferring Stockholder purchases all securities subject to the right of co-sale from such participating Preferred Stockholder(s) on the same terms and conditions (including the proposed purchase price) as set forth in the Transfer Notice; provided, however, if such sale constitutes a
Change of Control, the portion of the aggregate consideration paid by the Transferring Stockholder to such participating Preferred Stockholder(s) shall be made in accordance with Section 3.2(c) below. Subject to the foregoing and to the
provisions of Section 3.2(a) hereof, the Transferring Stockholder may, within ninety (90) days after the date of the Transfer Notice, transfer the Offered Securities (reduced by the number of equity securities with respect to which any of
the Preferred Stockholders have elected to participate, if any) at a price and on terms specified in the Transfer Notice; provided, that such transferee(s) first executes and delivers to the Company a written agreement to be bound by all of
the provisions of this Agreement applicable to Restricted Holders and naming the Company and the Preferred Stockholders as intended third-party beneficiaries of such agreement. If such Transfer is not consummated within such ninety (90) day
period, however, the Transferring Stockholder will not transfer any of the Offered Securities that have not been purchased within such period without again complying with all of the provisions of this Section 3. 

  
 - 10 - 

 The Preferred Stockholders shall effect their participation in the Transfer by
(A) converting the shares of Preferred Stock to be sold to Common Stock, if necessary, immediately prior to the completion of such Transfer, and (B) delivering to the Transferring Stockholder, on or prior to the Transfer Date, for transfer
to the prospective purchaser, one or more certificates, properly endorsed for transfer, which represent the number of shares of Common Stock that any such participating Preferred Stockholder elects to sell. In the event that such Preferred
Stockholder elects to sell less than all of the shares represented by any stock certificate in accordance with the terms hereof, upon surrender of such certificate to the Company, the Company shall promptly issue to such Preferred Stockholder both a
certificate representing that number of shares that such Preferred Stockholder elects to sell in such Transfer and a residual certificate representing the number of shares that will not be sold in such Transfer (the “Residual
Certificate”). The stock certificate or certificates representing shares that the participating Preferred Stockholder elects to sell shall be transferred to the prospective purchaser in consummation of the sale of the Common Stock
pursuant to the terms and conditions specified in the Transfer Notice and the Residual Certificate shall be returned to the participating Preferred Stockholder. Subject to Section 3.2(c) below, the Transferring Stockholder shall immediately
upon receipt of the proceeds from the sale of the Common Stock held by the participating Preferred Stockholders remit to each such participating Preferred Stockholder that portion of the proceeds to which such participating Preferred Stockholder is
entitled by reason of its participation in such sale. 
 (c) In the event that a proposed Transfer constitutes a Change of Control, the
aggregate consideration from such transfer shall be allocated to the participating Preferred Stockholder(s) and the Transferring Stockholder in accordance with Section 3 of Article IV(A) of the charter as if (i) such Transfer were a Deemed
Liquidation Event (as defined in the Charter), and (ii) the capital stock sold was the only capital stock outstanding. 
 (d)
Prohibited Transfers. In the event that a Restricted Holder should sell any equity securities in contravention of the first refusal rights or co-sale rights of the Preferred Stockholders under
Section 3.2(a) or Section 3.2(b) (a “Prohibited Transfer”), the Preferred Stockholders, in addition to such other remedies as may be available at law, in equity or hereunder, shall have the call option and put option
provided under this Section 3.2(d), and the Restricted Holder shall be bound by the applicable provisions of such option. In the event of a Prohibited Transfer in violation of the first refusal rights of the Preferred Stockholders, each
Preferred Stockholder shall have the right to send to such Transferring Stockholder the purchase price for such Offered Securities as is herein specified and transfer to the name of such Preferred Stockholder (or request that the Company effect such
transfer in the name of a Preferred Stockholder) on the Company’s books any certificates, instruments, or book entry representing the Offered Securities to be sold. In the event of a Prohibited Transfer in violation of the co-sale rights of the Preferred Stockholders, each Preferred Stockholder shall have the right to sell to the Restricted Holder making such Prohibited Transfer the type and number of shares of equity securities equal
to the number of shares each Preferred Stockholder would have been entitled to transfer to the third-party transferee(s) under this Section 3.2 had the Prohibited Transfer been effected pursuant to and in compliance with the terms hereof. Such
sale will be made on the 

  
 - 11 - 

 same terms and subject to the same conditions as would have applied had the Restricted Holder not made the
Prohibited Transfer, including that: 
 (i) The price per share at which the shares are to be sold to the Restricted Holder shall be equal
to the price per share paid by the third-party transferee(s) to the Restricted Holder in the Prohibited Transfer. The Restricted Holder shall also reimburse each Preferred Stockholder for any and all reasonable and documented out-of-pocket fees and expenses, including reasonable legal fees and expenses, incurred pursuant to the exercise or the attempted exercise of the Preferred Stockholder’s
rights under this Section 3.2. 
 (ii) Within ninety (90) days after the later of the date on which the Preferred Stockholder
(A) receives notice of the Prohibited Transfer or (B) otherwise becomes aware of the Prohibited Transfer, each Preferred Stockholder shall, if exercising the option created hereby, deliver to the Restricted Holder the certificate or
certificates representing shares to be sold, each certificate to be properly endorsed for transfer. 
 (iii) The Restricted Holder shall,
upon receipt of the certificate or certificates for the shares to be sold by a Preferred Stockholder pursuant to this Section 3.2(d), pay the aggregate purchase price therefor and the amount of reimbursable fees and expenses, as specified in
Section 3.2(d)(i), in cash or by other means acceptable to the Preferred Stockholder. 
 4. DRAG-ALONG RIGHT OF SECURITIES. 

4.1. Definitions Used in This Section. 

(a) “Buyer” shall have the meaning assigned to such term in Section 4.2(b). 

(b) “Drag-Along Notice” shall have the meaning assigned to such term in Section 4.2. 

(c) “Drag-Along Stockholders” shall mean, collectively, (i) the Preferred Stockholders, (ii) the Key Officers, and
(iii) the One Percent Common Stockholders. 
 (d) “Liquidation Event” means any liquidation, dissolution, or winding-up of the affairs of the Company, including an Acquisition, which entitles the stockholders of the Company to certain payments pursuant to Section A.3 of Article IV of the Charter. 

(e) “Proposed Sale” shall have the meaning assigned to such term in Section 4.2(c). 

(f) “Required Senior Preferred Holders” shall have the meaning assigned to such term in the Charter. 

(g) “Sale of the Company” means either: (i) a transaction or series of related transactions in which stockholders of the
Company representing more than 50% of the outstanding voting power of the Company sell their shares directly to a person or entity, or a group of related persons or entities (a “Stock Sale”); or (ii) a transaction that
qualifies as a “Liquidation Event”. 

  
 - 12 - 

 (h) “Selling Investors” shall have the meaning assigned to such term in
Section 4.2(a). 
 4.2. Actions to be Taken. 

(a) In the event that (i) the Board (other than in connection with a Stock Sale), by prior Super Board Approval, and (ii) the
Required Senior Preferred Holders (the “Selling Investors”) approve a Sale of the Company specifying that this Section 4 shall apply to such transaction, then the Company shall provide written notice of such approval (the
“Drag-Along Notice”) to each Drag-Along Stockholder and each Drag-Along Stockholder hereby agrees (subject to Section 4.2(c) below): 

(i) to vote (in person, by proxy or by action by written consent, as applicable), with respect to all Shares, in favor of such Sale of the
Company (and in favor of any related amendment to the Charter required in order to implement such Sale of the Company) and to vote in opposition to any and all other proposals that would result in a breach of any covenant, representation, warranty
or any other obligation or agreement of the Company under the definitive agreement(s) related to such Sale of the Company or which could delay or impair the ability of the Company to consummate such Sale of the Company, if such transaction requires
the approval of the Company’s stockholders; 
 (ii) if such transaction is a Stock Sale, to sell the same proportion of shares of
capital stock of the Company beneficially held by such Drag-Along Stockholder as is being sold by the Selling Investors to the person or entity to whom the Selling Investors propose to sell their Shares, and, except as permitted in
Section 4.2(c) below, on the same terms and conditions as the Selling Investors; 
 (iii) to execute and deliver all related
documentation and take such other action in support of the Sale of the Company as shall reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Section 4, including, without
limitation, executing and delivering instruments of conveyance and transfer, and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer
(free and clear of impermissible liens, claims and encumbrances), and any similar or related documents; 
 (iv) not to deposit, and to cause
its Affiliate Stockholders not to deposit, except as provided in this Agreement, any Shares of the Company owned by such Drag-Along Stockholder or Affiliate Stockholders in a voting trust or subject any such Shares to any arrangement or agreement
with respect to the voting of such securities, unless specifically requested to do so by the acquirer in connection with the Sale of the Company; 

  
 - 13 - 

 (v) to refrain from exercising any dissenters’ rights or rights of appraisal under
applicable law at any time with respect to such Sale of the Company; and 
 (vi) if the consideration to be paid in exchange for the Shares
pursuant to this Section 4.2 includes any securities and due receipt thereof by any Drag-Along Stockholder would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer
or agent with respect to such securities or (y) the provision to any Drag-Along Stockholder of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited
investors” as defined in Regulation D promulgated under the Securities Act of 1933, as amended, the Company may cause to be paid to any such Drag-Along Stockholder in lieu thereof, against surrender of the Shares which would have otherwise been
sold by such Drag-Along Stockholder, an amount in cash equal to the fair value (as determined in good faith by the Company) of the securities which such Drag-Along Stockholder would otherwise receive as of the date of the issuance of such securities
in exchange for the Shares. 
 (b) Drag-Along Notice. Each Drag-Along Notice required by Section 4.2(a) shall include reasonable
details of the Sale of the Company including, but not limited to, the following: (i) the proposed time and place of the closing of the Sale of the Company; (ii) the substantive terms and conditions of the Sale of the Company including
(A) the purchase price and terms of payment and (B) the identity, beneficial ownership (if known by any Selling Investors), address and telephone number of the third-party purchaser (the “Buyer”) having made the bona fide
offer; (iii) the number and class of capital stock of the Company held by the Buyer and its affiliates (if any) and the substantive terms and conditions of any previous transactions under which the Buyer or any of its affiliates purchased
capital stock of the Company from the Selling Investors, including the price per share at which such capital stock was purchased; (iv) the number and class of the Selling Investors’ shares; and (v) any written consent of stockholders,
stockholder resolutions (if the Sale of the Company is being approved at a stockholders’ meeting), agreement, instrument or other document the Drag-Along Stockholders are required to execute together with all exhibits, attachments and schedules
thereto. 
 (c) Exceptions. Notwithstanding the foregoing: 

(i) Without the prior written consent of the Majority Series G Holders, no Series G Stockholder that is a Drag Along Stockholder will be
required to comply with Section 4.2(a) above in connection with any proposed Sale of the Company (the “Proposed Sale”) unless each Series G Stockholder would reasonably be expected to receive, in connection with such Proposed
Sale, an amount in respect of each share of Series G Preferred Stock held by such Series G Stockholder at least equal to the Series G Liquidation Preference (as defined in the Charter); and 

  
 - 14 - 

 (ii) No Drag-Along Stockholder will be required to comply with Section 4.2(a) above in
connection with any Proposed Sale unless: 
 (A) any representations and warranties to be made by such Drag-Along Stockholder (other than
representations and warranties being made by a Drag-Along Stockholder in his or her capacity as a current or former employee of or consultant to the Company) in connection with the Proposed Sale are limited to representations and warranties related
to authority, ownership of the shares of Common Stock and/or Preferred Stock held by such Drag-Along Stockholder and the ability to convey title to such Shares, including but not limited to representations and warranties that (1) the Drag-Along
Stockholder holds all right, title and interest in and to the Shares such Drag-Along Stockholder purports to hold, free and clear of all liens and encumbrances, (2) the obligations of the Drag-Along Stockholder in connection with the
transaction have been duly authorized, if applicable, (3) the documents to be entered into by the Drag-Along Stockholder have been duly executed by the Drag-Along Stockholder and delivered to the acquirer and are enforceable against the
Drag-Along Stockholder in accordance with their respective terms and (4) neither the execution and delivery of documents to be entered into in connection with the transaction, nor the performance of the Drag-Along Stockholder’s obligations
thereunder, will cause a breach or violation of the terms of any agreement, law or judgment, order or decree of any court or governmental agency applicable to such Drag-Along Stockholder; 

(B) the Drag-Along Stockholder shall not be liable for the inaccuracy of any representation or warranty made by any other person in
connection with the Proposed Sale other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company as well as breach by any stockholder of
any of identical representations, warranties and covenants provided by all stockholders (an “Escrow”)); 
 (C) liability
for indemnification, if any, of the Drag-Along Stockholder for the inaccuracy of any representations and warranties, or for the breach of any covenant, made by the Company or its Stockholders in connection with such Proposed Sale, is several and not
joint with any other person (except to the extent that funds may be paid out of an Escrow) and is pro rata in proportion to, and does not exceed, the aggregate consideration receivable by such Drag-Along Stockholder (whether directly or out of an
Escrow) in the Proposed Sale; 
 (D) liability shall be limited to the amount of consideration actually paid to such Drag-Along Stockholder
in connection with such Proposed Sale, except with respect to claims related to fraud by such Drag-Along Stockholder, the liability for which need not be limited as to such Drag-Along Stockholder; 

(E) upon the consummation of the Proposed Sale, the aggregate consideration receivable by all holders of the Preferred Stock and Common Stock
shall be allocated among the holders of Preferred Stock and Common Stock on the basis of the relative liquidation preferences and amounts to which the holders of each respective series of Preferred Stock and the holders of Common Stock are entitled
in a Liquidation Event (assuming for this purpose that the Proposed Sale is a Liquidation Event even if it is structured as a Stock Sale) in accordance with the Charter in effect immediately prior to the Proposed Sale; and 

  
 - 15 - 

 (F) the Proposed Sale does not result in such Preferred Stockholder (or affiliate thereof)
having any obligation to agree to any: (i) covenant not to compete; (ii) covenant not to solicit customers, employees or suppliers of any party to the Proposed Sale (or affiliate thereof); or (iii) covenant to amend, modify or
terminate any contracts or commercial arrangements to which such Preferred Stockholder (or affiliate thereof) is a party. 
 (d) No
Interference. For avoidance of doubt, the obligations under this Section 4.2 shall not limit, restrict or otherwise interfere with the right of any Series E Holder, Series F Holder or Series G Holder to vote (in person, by proxy or by
action by written consent, as applicable) with respect to all shares of Series E Preferred Stock, Series F Preferred Stock or Series G Preferred Stock that such Series E Holder, Series F Holder or Series G Holder owns or over which such Series E
Holder, Series F Holder or Series G Holder otherwise exercises voting power, in any way such Series E Holder, Series F Holder or Series G Holder determines in its sole discretion with respect to any proposal on which the holders of Series E
Preferred Stock, Series F Preferred Stock or Series G Preferred Stock are entitled to vote as a separate series pursuant to the Charter, including without limitation, the right to approve an automatic conversion of the Series E Preferred Stock,
Series F Preferred Stock or Series G Preferred Stock into Common Stock. 
 (e) Restrictions on Sales of Control of the Company. No
Stockholder shall be a party to any Stock Sale unless all holders of Preferred Stock are allowed to participate in such transaction and the consideration received pursuant to such transaction is allocated among the parties thereto in the manner
specified in the Company’s Charter in effect immediately prior to the Stock Sale (as if such transaction were a Deemed Liquidation Event), unless (i) the Required Senior Preferred Holders, (ii) holders holding at least 60% of the then
outstanding shares of Series E Preferred Stock voting together as a single class, (iii) holders holding at least 60% of the then outstanding shares of Series F Preferred Stock, and (iv) holders holding at least 55% of the then outstanding
shares of Series G Preferred Stock, voting together as a single class elect otherwise by written notice given to the Company on or prior to consummation of such transaction or series of related transactions. 

(f) Consent Required to Amend, Terminate or Waive. This Section 4 may be amended or terminated and the observance of any term
hereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed by (a) the Company; (b) the Drag-Along Stockholders holding at least a majority of the
Shares then held by the Drag-Along Stockholders then subject to this Section 4; (c) the Required Senior Preferred Holders; (d) the Required Series E Holders; and (e) the Required Series F Holders. Notwithstanding the foregoing: 

(i) no term or provision of this Section 4 applicable to the Drag-Along Stockholders may be amended or terminated or the observance
thereof waived with respect to or on behalf of the Drag-Along Stockholders in a manner that effects the various constituencies 

  
 - 16 - 

 
thereof (i.e., the Preferred Stockholders, the Key Officers or the One Percent Common Stockholders) differently from one another without the written consent of the Preferred Stockholders (by
Preferred Stockholders holding at least a majority of the Shares held by the Preferred Stockholders), the Key Officers (by Key Officers holding at least a majority of the Shares held by the Key Officers) or the One Percent Common Stockholders (by
One Percent Common Stockholders holding at least a majority of the Shares held by the One Percent Common Stockholders), as the case may be; 

(ii) the consent of the Drag-Along Stockholders shall not be required for any amendment or waiver if such amendment or waiver either
(A) is not directly applicable to the rights of the Drag-Along Stockholders hereunder or (B) does not adversely affect the rights of the Drag-Along Stockholders in a manner that is different from the effect on the rights of the other
parties hereunder; and 
 (iii) Section 4.2(d) may not be amended or terminated and the observance of that provision may not be waived
without the consent of (A) the Required Series E Holders as it relates to the rights of the Series E Holders, (B) the Required Series F Holders as it relates to the rights of the Series F Holders and/or (C) the Required Series G
Holders as it relates to the rights of the Series G Holders. 
 (iv) Section 4.2(c)(i) may not be amended or terminated and the observance
of that provision may not be waived without the consent of the Majority Series G Holders. 
 5. PROCEDURES FOR INVOLUNTARY TRANSFERS. 

5.1. Transfers by Operation of Law. In the event that any Restricted Holder, Series A-2 Holder, Series B Holder,
Series C Holder, Series D Holder, Series E Holder, Series F Holder or Series G Holder: (i) files a voluntary petition under any bankruptcy or insolvency law or a petition for the appointment of a receiver or makes an assignment for the benefit
of creditors, (ii) is subjected involuntarily to such a petition or assignment or to an attachment or other legal or equitable interest with respect to any equity securities of the Company and such involuntary petition or assignment or
attachment is not discharged within 90 days, or (iii) is subjected to any other possible transfer of any equity securities of the Company by operation of law, including, without limitation, an assignment pursuant to a divorce decree or other
similar proceeding, then such Restricted Holder, Series A-2 Holder, Series B Holder, Series C Holder, Series D Holder, Series E Holder, Series F Holder or Series G Holder will notify the Company and each
Preferred Stockholder of such event and the Company and each such Preferred Stockholder will have an option to purchase from any receiver, petitioner, assignee, transferee or other person obtaining an interest in such equity securities (a
“Transferee by Law”) all or any portion of such equity securities and all interests therein as if, and upon the same terms and conditions as if, at the time of such event such Transferee by Law had given a Transfer Notice in
accordance with the provisions of Section 3.1 of this Agreement, stating a price equal to the Fair Market Value of such equity securities (as determined in accordance with Section 5.2 hereof); provided, that the time period during which
the Company and the Preferred Stockholders may elect to exercise their options to purchase such equity securities of the Transferee by Law will not begin to run 

  
 - 17 - 

 
until such transferring Restricted Holder, Series A-2 Holder, Series B Holder, Series C Holder, Series D Holder, Series E Holder, Series F Holder or
Series G Holder gives actual written notice of the transfer of such equity securities to the Company and the Preferred Stockholders in accordance with Section 10.2 hereof. 

5.2. Determination of Fair Market Value. For the purposes of this Agreement, the “Fair Market Value” of securities of the Company will
be determined in good faith by the Board of Directors, which determination must include the affirmative vote or consent by Super Board Approval. 
 6.
RESTRICTIVE LEGENDS. For so long as this Agreement remains in effect, the certificates representing any shares of capital stock or other securities of the Company held by any Restricted Holder will bear a restrictive legend in substantially the
following form: 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS WITH RESPECT TO THE VOTING AND
THE TRANSFER OF SUCH SECURITIES SET FORTH IN THE SIXTH AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT DATED AS OF JUNE 1, 2017 (AS AMENDED AND/OR RESTATED AND IN EFFECT FROM TIME TO TIME), BY AND AMONG THE ISSUER OF SUCH SECURITIES AND THE
REGISTERED HOLDER OF THIS CERTIFICATE (OR SUCH HOLDER’S PREDECESSOR-IN-INTEREST) AND CERTAIN OTHERS. A COPY OF SUCH AGREEMENT IS ON FILE AND MAY BE INSPECTED BY THE
REGISTERED HOLDER OF THIS CERTIFICATE AT THE PRINCIPAL EXECUTIVE OFFICE OF THE ISSUER.” 
 7. TERMINATION OF AGREEMENT. Except as provided in
Section 4.2(e), this Agreement, and all restrictions on transfer and other provisions contained herein, will terminate upon the earliest to occur of: (a) the closing of a Qualified Public Offering; (b) an Acquisition in connection
with which the stockholders of the Company receive cash and/or unrestricted securities that are actively traded on a national securities exchange and are of an entity subject to and in compliance with the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, provided that, if applicable, the provisions of Section 4 hereof will continue after the closing of any Sale of the Company to the extent necessary to enforce the provisions of
Section 4 with respect to such Sale of the Company; or (c) termination of this Agreement in accordance with Section 10.1 below. 
 8.
ADDITIONAL STOCKHOLDERS. Any Person that is or becomes (i) a holder of record of shares of any class or series of capital stock of the Company or (ii) a Key Officer, may become a party to this Agreement by executing and delivering to
the Company an Instrument of Adherence, substantially in the form of Exhibit A attached hereto; provided, that the Company consents to such Person becoming a party to this Agreement (which consent shall be

  
 - 18 - 

 
conclusively deemed to have been given by the Company if and when the Company countersigns the Instrument of Adherence executed by such Person). In addition, the Company agrees that it shall not
issue any securities to (x) any Key Officer, (y) any Person who, together with their Affiliates, after such acquisition would be a One Percent Common Stockholder or (z) any Person who purchases shares of Preferred Stock upon the
exercise of Derivative Securities, unless such Key Officer or Person executes and delivers an Instrument of Adherence to this Agreement. Any such Instrument of Adherence executed by any such Key Officer or Person and countersigned by the Company
shall become a part of this Agreement. It is hereby understood and agreed that such Key Officer or Person may become a party to this Agreement without having to obtain the signature, consent, approval or permission of any of the parties hereto other
than the Company and that, immediately upon such Key Officer or Person becoming a party to this Agreement, such Key Officer or Person shall be deemed to be a Common Stockholder, One Percent Common Stockholder, Key Officer, Series A-1 Holder, Series A-2 Holder, Series B Holder, Series C Holder, Series D Holder, Series E Holder, Series F Holder or Series G Holder hereunder, as the case may be, and the
Schedule of Common Stockholders, the Schedule of Key Officers, the Schedule of Series A-1 Stockholders, the Schedule of Series A-2
Stockholders, the Schedule of Series B Stockholders, the Schedule of Series C Stockholders, the Schedule of Series D Stockholders, the Schedule of Series E Stockholders, the Schedule of Series F Stockholders or
the Schedule of Series G Stockholders, as the case may be, shall be updated automatically without any action required by the parties hereto. 
 9.
“BAD ACTOR” MATTERS. 
 9.1. Representation. 

Each Person with the right to designate or participate in the designation of a director pursuant to this Agreement hereby represents that none of the “bad
actor” disqualifying events described in Rule 506(d)(1)(i)-(viii) promulgated under the Securities Act (a “Disqualification Event”) is applicable to such Person or any of its Rule 506(d) Related Parties, except, if applicable,
for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable. For purposes of this Agreement, “Rule 506(d) Related Party” shall mean with respect to any Person any other Person that is a beneficial
owner of such first Person’s securities for purposes of Rule 506(d) of the Securities Act. 
 9.2. Covenant. 

Each Person with the right to designate or participate in the designation of a director pursuant to this Agreement hereby agrees that it shall notify the
Company promptly in writing in the event a Disqualification Event becomes applicable to such Person or any of its Rule 506(d) Related Parties, except, if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3)
is applicable. 
 10. MISCELLANEOUS PROVISIONS. 

10.1. Amendments, Consents, Waivers, Etc. 

  
 - 19 - 

 (a) Except as otherwise provided in this Agreement, this Agreement or any provision hereof may be
amended or terminated by the written agreement of the Company and the Stockholders then party to this Agreement holding at least 60% of the Shares then held by all Stockholders (on an as-converted to Common
Stock basis). The observance of any provision of this Agreement that is for the specific benefit of the Series A-2 Holders, Series B Holders, Series C Holders, the Series D Holders, the Series E Holders, the
Series F Holders or the Series G Holders may be waived (either generally or in a particular instance, and either retroactively or prospectively), and any consent, approval or other action to be given or taken specifically by the Series A-2 Holders, Series B Holders, Series C Holders, the Series D Holders, the Series E Holders, the Series F Holders or the Series G Holders pursuant to this Agreement may be given or taken, by the consent of the
Majority Series A-2 Holders, the Majority Series B Holders, the Majority Series C Holders, the Required Series D Holders, the Required Series E Holders, the Required Series F Holders or the Majority Series G
Holders, as the case may be. Notwithstanding anything to the contrary herein, the rights of any of the specific Series A-2 Holders provided under Section 1.2(ii)(a) of this Agreement, the rights of any of
the specific Series B Holders provided under Section 1.2(ii)(b) of this Agreement, the rights of any of the specific Series C Holders provided under Section 1.2(ii)(c) of this Agreement, the rights of any of the specific Series D Holders
provided under Section 1.2(ii)(d) of this Agreement and the rights of Polaris provided under Section 1.2(ii)(e) of this Agreement shall not be amended without such party’s consent, and may be waived only by such party. The observance
of any provision of this Agreement that is for the specific benefit of the Series A-1 Holders may be waived (either generally or in a particular instance, and either retroactively or prospectively), and any
consent, approval or other action to be given or taken specifically by the Series A-1 Holders pursuant to this Agreement may be given or taken by, the consent of holders of record of a majority of the shares
of the Series A-1 Preferred Stock then held by Series A-1 Holders. The observance of any provision of this Agreement that is for the specific benefit of the Common
Stockholders may be waived (either generally or in a particular instance, and either retroactively or prospectively), and any consent, approval or other action to be given or taken specifically by the Common Stockholders pursuant to this Agreement
may be given or taken, by the consent of Common Stockholders holding at least a majority of the shares of the Company’s Common Stock then held by Common Stockholders. Subject to the foregoing provisions of this paragraph, any Stockholder may in
writing waive, as to him-, her- or itself only, the benefits of any provision of this Agreement. Notwithstanding any provision contained herein to the contrary, no such
amendment, termination or waiver shall adversely affect any Stockholder, Series A-1 Holder, Series A-2 Holder, Series B Holder, Series C Holder, Series D Holder, Series
E Holder, Series F Holder or Series G Holder in a manner different from or disproportionate to any other Stockholder, Series A-1 Holder, Series A-2 Holder, Series B
Holder, Series C Holder, Series D Holder, Series E Holder, Series F Holder or Series G Holder, respectively, without such party’s consent. 

(b) No course of dealing between or among any of the parties to this Agreement will operate as a waiver of any rights under this Agreement. No
waiver of any breach or default hereunder will be valid unless in writing signed by the waiving party. No failure or other delay by any person in exercising any right, power or privilege hereunder will be or operate as a waiver thereof, nor will any
single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 

  
 - 20 - 

 (c) The Company shall give prompt notice of any amendment or termination hereof or waiver
hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 10.1 shall be binding on all parties hereto, regardless of
whether any such party has consented thereto. 
 10.2. Notices. All notices, requests, payments, instructions or other documents to be given
hereunder will be in writing or by written telecommunication, and will be deemed to have been duly given if (i) delivered personally (effective upon delivery), (ii) mailed by certified mail, return receipt requested, postage prepaid
(effective five business days after dispatch), (iii) sent by a reputable, established courier service that provides evidence of delivery and guarantees next business day delivery (effective the next business day), or (iv) sent by
telecopier or email followed within 24 hours by confirmation by one of the foregoing methods (effective upon receipt of the telecopy or email in complete, readable form), addressed as follows: 

(a) If to the Company: 

Neuronetics, Inc. 

3222 Phoenixville Pike 

Malvern, Pennsylvania 19355 

Attention: Chief Executive Officer 

Telecopier No. (610) 482-9986 

with a copy (which shall not constitute notice) to: 

Christopher S. Miller and Timothy C. Atkins 

Pepper Hamilton LLP 

400 Berwyn Park 

899 Cassatt Road 

Berwyn, PA 19312-1183 

Telecopier No. (610) 640-7835 

(b) If to any Series G Holder, the address and telecopier information set forth on the Schedule of Series G Stockholders attached hereto, with
copies (which shall not constitute notice) to: 
 Michael H. Bison 

Goodwin Procter LLP 

100 Northern Avenue 

Boston, Massachusetts 02210 

  
 - 21 - 

 (c) If to any Series F Holder, the address and telecopier information set forth on the Schedule
of Series F Stockholders attached hereto, with copies (which shall not constitute notice) to: 
 Deborah Marshall 

Sidley Austin LLP 

1001 Page Mill Road, Building 1 

Palo Alto, CA 94304 

(d) If to any Series E Holder, the address and telecopier information set forth on the Schedule of Series E Stockholders attached hereto, with
copies (which shall not constitute notice) to: 
 Jay K. Hachigian 

Gunderson Dettmer Stough Villeneuve 

Franklin & Hachigian, LLP 

850 Winter Street 

Waltham, MA 02451 

Telecopier No. (781) 622-1622 

(e) If to any Series D Holder, the address and telecopier information set forth on the Schedule of Series D Holders attached hereto, with a
copy (which shall not constitute notice) to: 
 Amy Paye 

Cooley Godward Kronish LLP 

Five Palo Alto Square 

3000 El Camino Real 

Palo Alto, CA 94306-2155 

Telecopier No. (650) 618-1601 

(f) If to any Series C Holder, the address and telecopier information set forth on the Schedule of Series C Holders attached hereto, with a
copy (which shall not constitute notice) to: 
 P. Sherrill Neff 

Quaker BioVentures 

Cira Centre, 2929 Arch Street 

Philadelphia, PA 19104-2868 

(g) If to any Series B Holder, the address and telecopier information set forth on the Schedule of Series B Holders attached hereto, with
copies (which shall not constitute notice) to: 
 J. Casey McGlynn 

Wilson Sonsini Goodrich & Rosati 

650 Page Mill Road 

Palo Alto, CA 94304-1050 

Telecopier No (650) 493-6811 

  
 - 22 - 

 Three Arch Partners 

3200 Alpine Road 

Portola Valley, CA 94028 

Attn: Richard Lin 

(h) If to any Series A-2 Holder, the address and telecopier information set forth on the Schedule of
Series A-2 Stockholders attached hereto, with copies (which shall not constitute notice) to: 

Gloria M. Skigen 

Holland & Knight 

One Stamford Plaza 

263 Tresser Blvd. 

Stamford, CT 06901-3271 

Telecopier:: (203) 724-1576 

Stephen Campe, Managing Director 

Investor Growth Capital, Inc. 

c/o Patricia Industries 

1177 Avenue of the Americas, 47th Floor 

New York, NY 10036 

Telecopier: (212) 515-9039 

(i) If to any Series A-1 Holder, the address and telecopier information set forth on the Schedule of
Series A-1 Stockholders attached hereto, with a copy (which shall not constitute notice) to: 

Jeffrey K. Haidet 

McKenna Long Aldridge 

303 Peachtree Street, Suite 5300 

Atlanta, GA 30308 

Telecopier no. (404) 527-4198 

(j) If to any Common Stockholder or to any Key Officers, the address and telecopier information set forth on the Schedule of Common
Stockholders, the Schedule of Key Officers attached hereto or the Instrument of Adherence, as the case may be. 
 10.3. Pepper Hamilton
Representation. Each of the Stockholders and the Company acknowledges that Pepper Hamilton LLP (“Pepper”) may have represented and may currently represent certain of the Stockholders or their affiliates. In the course of such
representation, Pepper may have come into possession of confidential information relating to such Stockholders 

  
 - 23 - 

 
or affiliates. Each of the Stockholders and the Company acknowledges that Pepper is representing only the Company in the transactions contemplated by this Agreement. Pursuant to Rule 1.7 of the
Rules of Professional Conduct adopted by the Supreme Court of Pennsylvania, an attorney must avoid representations in which the attorney has or had a relationship with another party interested in the representation without the informed written
consent of all parties affected. By executing this Agreement, each of the Stockholders and the Company hereby consents to Pepper’s representation of the Company in the transactions contemplated by this Agreement and Pepper’s previous or
continuing representation of one or more of the Stockholders or their affiliates in matters unrelated to such transactions. 
 10.4. Counterparts.
This Agreement may be executed by the parties in separate counterparts, each of which when so executed and delivered will be an original, but all of which together will constitute one and the same agreement. In pleading or proving this Agreement, it
will not be necessary to produce or account for more than one such counterpart. Each party hereto will receive by delivery, facsimile transmission or electronic mail a duplicate original of this Agreement executed by each party, and each party
agrees that the delivery of this Agreement by facsimile transmission or by electronic mail in “portable document format” will be deemed to be an original of this Agreement so transmitted. 

10.5. Captions. The captions of sections or subsections of this Agreement are for reference only and will not affect the interpretation or construction
of this Agreement. 
 10.6. Binding Effect and Benefits. This Agreement will bind and inure to the benefit of the parties hereto and their respective
successors and permitted transfers and assigns. Except as otherwise provided in this Agreement, the provisions of this Agreement that are for the Series A-2 Holders’ benefit, as the holders of Series A-2 Preferred Stock, will inure to the benefit of all permitted transferees of such Series A-2 Holders, and the applicable provisions of this Agreement that bind the Series A-2 Holders will bind all permitted transferees of such Series A-2 Preferred Stock. Except as otherwise provided in this Agreement, the provisions of this Agreement that are
for the Series B Holders’ benefit, as the holders of Series B Preferred Stock, will inure to the benefit of all permitted transferees of such Series B Holders, and the applicable provisions of this Agreement that bind the Series B Holders will
bind all permitted transferees of such Series B Preferred Stock. Except as otherwise provided in this Agreement, the provisions of this Agreement that are for the Series C Holders’ benefit, as the holders of Series C Preferred Stock, will
inure to the benefit of all permitted transferees of such Series C Holders, and the applicable provisions of this Agreement that bind the Series C Holders will bind all permitted transferees of such Series C Preferred Stock. Except as otherwise
provided in this Agreement, the provisions of this Agreement that are for the Series D Holders’ benefit, as the holders of Series D Preferred Stock, will inure to the benefit of all permitted transferees of such Series D Holders, and
the applicable provisions of this Agreement that bind the Series D Holders will bind all permitted transferees of such Series D Preferred Stock. Except as otherwise provided in this Agreement, the provisions of this Agreement that are for
the Series E Holders’ benefit, as the holders of any Series E Preferred Stock, will inure to the benefit of all permitted transferees of such Series E Holders, and the applicable provisions of this Agreement that bind the Series
E 

  
 - 24 - 

 
Holders will bind all permitted transferees of such Series E Preferred Stock. Except as otherwise provided in this Agreement, the provisions of this Agreement that are for Series F Holders’
benefit, as the holders of Series F Preferred Stock, will inure to the benefit of all permitted transferees of such Series F Holders, and the applicable provisions of this Agreement that bind the Series F Holders will bind all permitted transferees
of such Series F Preferred Stock. Except as otherwise provided in this Agreement, the provisions of this Agreement that are for Series G Holders’ benefit, as the holders of Series G Preferred Stock, will inure to the benefit of all permitted
transferees of such Series G Holders, and the applicable provisions of this Agreement that bind the Series G Holders will bind all permitted transferees of such Series G Preferred Stock. 

10.7. Construction. The language used in this Agreement is the language chosen by the parties to express their mutual intent and no rule of strict
construction will be applied against any party. 
 10.8. Entire Agreement. This Agreement together with the exhibits and schedules hereto and the
transactions contemplated hereby contain the entire understanding and agreement among the parties, or between or among any of them, and supersedes any prior or contemporaneous understandings or agreements between or among any of them, with respect
to the subject matter hereof, including the Prior Agreement; provided however, that any right of first refusal contained in an option agreement to which an individual and the Company may be a party is superseded only for so long as such
individual is a Key Officer or a One Percent Common Stockholder and consequently subject to the provisions of Section 3 hereof. 
 10.9.
Severability. No invalidity or unenforceability of any section of this Agreement or any portion thereof will affect the validity or enforceability of any other section or the remainder of such section. 

10.10. Equitable Relief. Each of the parties acknowledges that any breach by such party of his, her or its obligations under this Agreement would cause
substantial and irreparable damage to one or more of the other parties and that money damages would be an inadequate remedy therefor. Accordingly, each party agrees that the other parties or any of them will be entitled to an injunction, specific
performance and/or other equitable relief to prevent the breach of such obligations. 
 10.11. Governing Law. This Agreement will be governed by and
interpreted and construed in accordance with the internal laws of the State of Delaware, as applied to agreements under seal made, and entirely to be performed, within Delaware. 

10.12. Assignment of Rights. The rights of the Preferred Stockholders under this Agreement may be assigned, in whole or in part, to (i) any
Affiliate Stockholder or (ii) an assignee or transferee who, after such assignment or transfer, holds at least five percent (5%) of the outstanding shares of capital stock of the Company on a fully-diluted basis (as adjusted for any stock
combination, stock split, stock dividend, recapitalization or other similar transaction), it being acknowledged and agreed that any such assignment, including an assignment contemplated 

  
 - 25 - 

 
by the preceding clauses (i) or (ii) shall be subject to and conditioned upon any such assignee’s delivery to the Company and the other Stockholders of an Instrument of Adherence
pursuant to which such assignee shall confirm their agreement to be subject to and bound by all of the provisions set forth in this Agreement that were applicable to the assignor of such assignee. Except as specifically permitted hereby, no party
hereto may assign its rights or delegate its obligations under this Agreement without (i) the prior written consent of the Company (which shall not be unreasonably withheld, delayed or conditioned) and (ii) complying with Section 4.4
of the Series G Purchase Agreement, and any attempted assignment or delegation without such consent or compliance will be void and of no effect. Nothing in this Agreement will confer any rights or remedies on any person other than the parties hereto
and their respective successors and permitted assigns. 
 10.13. Jurisdiction. The parties hereto agree that any suit, action or proceeding
instituted against one or more of them with respect to this Agreement (including any exhibits hereto) shall be brought in federal court in the Southern District of New York. The parties hereto, by the execution and delivery of this Agreement,
irrevocably waive any obligation or any right of immunity on the ground of venue, the convenience of the forum or the jurisdiction of such court, or from the execution of judgments resulting therefrom, and the parties hereto irrevocably accept and
submit to the jurisdiction of the aforesaid court in any suit, action or proceeding and consent to the service of process by certified mail at the address specified in Section 10.2 hereof. 

11. AGGREGATION OF STOCK. All Shares held or acquired by a Stockholder and/or its Affiliates shall be aggregated together for the purpose of
determining the availability of any rights or of any obligations under this Agreement, and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

12. REMEDIES. In case any one or more of the covenants and/or agreements set forth in this Agreement shall have been breached by any party hereto, the
party or parties entitled to the benefit of such covenants or agreements may proceed to protect and enforce its or their rights, either by suit in equity and/or action at law, including, but not limited to, an action for damages as a result of any
such breach and/or an action for specific performance of any such covenant or agreement contained in this Agreement. The rights, powers and remedies of the parties under this Agreement are cumulative and not exclusive of any other right, power or
remedy which such parties may have under any other agreement or law. No single or partial assertion or exercise of any right, power or remedy of a party hereunder shall preclude any other or further assertion or exercise thereof. 

13. OWNERSHIP. Each Restricted Holder represents and warrants that such Restricted Holder is the sole legal and beneficial owner of the shares of
capital stock subject to this Agreement and that no other person or entity has any interest in such shares (other than a community property interest as to which the holder thereof has acknowledged and agreed in writing to the restrictions and
obligations hereunder). 
 14. SPOUSAL CONSENT. If any individual Stockholder is married on the date of this Agreement, to the extent required by
applicable law of such Stockholder’s state of residence in 

  
 - 26 - 

 
connection with a transfer of shares of capital stock of the Company, such Stockholder’s spouse shall execute and deliver to the Company a consent of spouse in the form of Exhibit B
hereto (“Consent of Spouse”), effective on the date hereof. Notwithstanding the execution and delivery thereof, such consent shall not be deemed to confer or convey to the spouse any rights in such Stockholder’s Shares that do
not otherwise exist by operation of law or the agreement of the parties. If any individual Stockholder should marry or remarry subsequent to the date of this Agreement, such Stockholder shall within thirty (30) days thereafter obtain his/her
new spouse’s acknowledgement of and consent to the existence and binding effect of all restrictions contained in this Agreement by causing such spouse to execute and deliver a Consent of Spouse acknowledging the restrictions and obligations
contained in this Agreement and agreeing and consenting to the same. 
 [The rest of this page is intentionally left blank.] 

  
 - 27 - 

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

							
	COMPANY:	 		 	NEURONETICS, INC.
				
		 		 	By:	 	 /s/ Christopher Thatcher

		 		 	Name:	 	Christopher Thatcher
		 		 	Title:	 	President and Chief Executive Officer

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

							
	STOCKHOLDERS:	 		 	CHV IV, L.P.
				
		 		 	 By
	 	 Ascension Health Ventures IV, LLC,
 Its General
Partner

				
		 		 	By:	 	 /s/ Matthew I. Hermann

		 		 		 	 Name: Matthew I. Hermann
 Title: Senior
Managing Director

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

							
	STOCKHOLDERS:	 		 	GE VENTURES LIMITED
				
		 		 	By:	 	 /s/ David Mayhew

		 		 	Name:	 	David Mayhew
		 		 	Title:	 	Authorized Signatory

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

							
	STOCKHOLDERS:	 		 	INVESTOR GROWTH CAPITAL LIMITED
				
		 		 	By:	 	 /s/ Michael V. Oporto

		 		 	Name:	 	Michael V. Oporto
		 		 	Title:	 	Director
			
		 		 	INVESTOR GROUP, L.P.
		 		 	By: Investor Growth Capital, LLC, its General Partner
				
		 		 	By:	 	 /s/ Michael V. Oporto

		 		 		 	Name: Michael V. Oporto
		 		 		 	Title:   Secretary
			
		 		 	IGC FUND VI, L.P.
		 		 	By: Investor Growth Capital, LLC, its General Partner
				
		 		 	By:	 	 /s/ Michael V. Oporto

		 		 		 	Name: Michael V. Oporto
		 		 		 	Title:   Secretary

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

									
	STOCKHOLDERS:	 		 	ONSET IV, L.P.
				
		 		 	By:	 	 ONSET IV Management, LLC

its General Partner

					
		 		 		 	By:	 	 /s/ Rob Kuhling

		 		 		 	Name:	 	Rob Kuhling
		 		 		 	Title:	 	

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

									
	STOCKHOLDERS:	 		 	INTERWEST INVESTORS VIII, L.P.
				
		 		 	By:	 	 InterWest Management Partners VIII, LLC,

its General Partner

					
		 		 		 	By:	 	 /s/ Gilbert H. Kliman

		 		 		 	Name:	 	Gilbert H. Kliman
		 		 		 	Title:	 	Manging Director
			
		 		 	INTERWEST PARTNERS VIII, L.P.
				
		 		 	 By:
	 	 InterWest Management Partners VIII, LLC,

its General Partner

					
		 		 		 	By:	 	 /s/ Gilbert H. Kliman

		 		 		 	Name:	 	Gilbert H. Kliman
		 		 		 	Title:	 	Manging Director
			
		 		 	INTERWEST INVESTORS Q VIII, L.P.
				
		 		 	 By:
	 	 InterWest Management Partners VIII, LLC,

its General Partner

					
		 		 		 	By:	 	 /s/ Gilbert H. Kliman

		 		 		 	Name:	 	Gilbert H. Kliman
		 		 		 	Title:	 	Manging Director

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

									
	STOCKHOLDERS:	 		 	KBL HEALTHCARE, L.P.
				
		 		 	By:	 	KBL SBIC, Inc., its General Partner
					
		 		 		 	By:	 	 /s/ Marlene Krauss

		 		 		 	Name:	 	Marlene Krauss
		 		 		 	Title:	 	
			
		 		 	 KBL PARTNERSHIP, L.P.

				
		 		 	By:	 	KBL Healthcare, LLC, its General Partner
					
		 		 		 	By:	 	 /s/ Marlene Krauss

		 		 		 	Name:	 	Marlene Krauss
		 		 		 	Title:	 	
			
		 		 	 KBL HEALTHCARE VENTURES, L.P.

				
		 		 	By:	 	KBL Healthcare, LLC its General Partner
					
		 		 		 	By:	 	 /s/ Marlene Krauss

		 		 		 	Name:	 	Marlene Krauss
		 		 		 	Title:	 	

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

									
	STOCKHOLDERS:	 		 	THREE ARCH PARTNERS IV, L.P.
				
		 		 	 By:
	 	 Three Arch Management IV, L.L.C., its

General Partner

					
		 		 		 	By:	 	 /s/ Wilfred Jaeger

		 		 		 	Name:	 	Wilfred Jaeger
		 		 		 	Title:	 	Managing Member
			
		 		 	THREE ARCH ASSOCIATES IV, L.P.
				
		 		 	 By:
	 	 Three Arch Management IV, L.L.C., its

General Partner

					
		 		 		 	By:	 	 /s/ Wilfred Jaeger

		 		 		 	Name:	 	Wilfred Jaeger
		 		 		 	Title:	 	Managing Member
			
		 		 	THREE ARCH CAPITAL, L.P.
				
		 		 	 By:
	 	 Three Arch Management IV, L.L.C., its

General Partner

					
		 		 		 	By:	 	 /s/ Wilfred Jaeger

		 		 		 	Name:	 	Wilfred Jaeger
		 		 		 	Title:	 	Managing Member
			
		 		 	TAC ASSOCIATES, L.P.
				
		 		 	By:	 	 TAC Management, L.L.C., its
 its
General Partner

					
		 		 		 	By:	 	 /s/ Wilfred Jaeger

		 		 		 	Name:	 	Wilfred Jaeger
		 		 		 	Title:	 	Managing Member

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

									
	STOCKHOLDERS:	 		 	AMV PARTNERS I, L.P.
		 		 	By:	 	 Accuitive Medical Ventures, LLC.,

its General Partner

					
		 		 		 	By:	 	 /s/ Thomas Weldon

		 		 		 	Name:	 	Thomas Weldon
		 		 		 	Title:	 	

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

							
	STOCKHOLDERS:	 		 	QPIV, LLC
				
		 		 	By:	 	 /s/ P. Sherrill Neff

		 		 	Name: P. Sherrill Neff
		 		 	Title: Authorized Member on behalf of Quaker Partners

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

							
	STOCKHOLDERS:	 		 	Industry Ventures Healthcare, L.L.C.
			
		 		 	 By: Industry Ventures Management VII, L.L.C.,

its General Partner

				
		 		 	By:	 	 /s/ Justin Burden

		 		 		 	      Name: Justin Burden

     Title:   Member

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

			
	 STOCKHOLDERS:
	  	   NEW LEAF VENTURES II, L.P.

    

By:        New Leaf Venture Associates II, L.P.

Its:         General Partner

    

By:        New Leaf Venture Management II, L.L.C.

Its:         General Partner

    

By:        /s/ Craig
Slutzkin                                        
    

              Name: Craig Slutzkin

              Title:   Chief Financial
Officer

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

			
	 STOCKHOLDERS:
	  	 POLARIS VENTURE PARTNERS V, L.P.

    

By:    Polaris Venture Management Co. V, L.L.C.,

          Its General Partner

    

By:    /s/ Max
Eisenberg                                        

           Max Eisenberg, Attorney-in-Fact
     

POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND V, L.P.

    

By:    Polaris Venture Management Co. V, L.L.C.,

          Its General Partner

    

By:    /s/ Max
Eisenberg                                        

           Max Eisenberg, Attorney-in-Fact
     

POLARIS VENTURE PARTNERS FOUNDERS’ FUND V, L.P.

    

By:    Polaris Venture Management Co. V, L.L.C.,

          Its General Partner

    

By:    /s/ Max
Eisenberg                                        

           Max Eisenberg, Attorney-in-Fact
     

POLARIS VENTURE PARTNERS SPECIAL FOUNDERS’ FUND V, L.P.

    

By:    Polaris Venture Management Co. V, L.L.C.,

          Its General Partner

    

By:    /s/ Max
Eisenberg                                        

           Max Eisenberg, Attorney-in-Fact

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

 

			
	 STOCKHOLDERS:
	  	   PFIZER INC.

    

By:        /s/ Barbara
Dalton                                        
    
 Name: Barbara Dalton

Title: Vice President

 [Signature Page to Sixth Amended and Restated Stockholders’ Agreement] 

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written by the Company and the Stockholders listed below. 

STOCKHOLDERS: 

	
	
	 /s/ Brian Farley

	Brian Farley

 Schedule of Series G Stockholders 

CHV IV, L.P. 
 GE Ventures Limited 

Polaris Venture Partners V, L.P. 
 Polaris Venture
Partners Entrepreneurs’ Fund V, L.P. 
 Polaris Venture Partners Special Founders’ Fund V, L.P. 

Polaris Venture Partners Founders’ Fund V, L.P. 

Pfizer Inc. 
 New Leaf Ventures II, L.P. 

Industry Ventures Healthcare, L.L.C. 
 Three Arch
Partners IV, L.P. 
 Three Arch Associates IV, L.P. 

Three Arch Capital, L.P. 
 TAC Associates L.P. 

 IGC Fund VI, L.P. 

ONSET IV, L.P. 
 InterWest Partners VIII, L.P.

 InterWest Investors VIII, L.P. 
 InterWest
Investors Q VIII, L.P. 
 KBL Partnership, L.P. 

KBL Healthcare Ventures, L.P. 
 AMV Partners I, L.P.

 Brian Farley 

 Schedule of Series F Stockholders 

GE Ventures Limited 
 Polaris Venture Partners V, L.P.

 Polaris Venture Partners Entrepreneurs’ Fund V, L.P. 

Polaris Venture Partners Special Founders’ Fund V, L.P. 

Polaris Venture Partners Founders’ Fund V, L.P. 

Pfizer Inc. 
 New Leaf Ventures II, L.P. 

QPIV, LLC 
 Three Arch Partners IV, L.P. 

Three Arch Associates IV, L.P. 
 Three Arch Capital,
L.P. 
 TAC Associates L.P. 

 IGC Fund VI, L.P. 

ONSET IV, L.P. 
 InterWest Partners VIII, L.P.

 InterWest Investors VIII, L.P. 
 InterWest
Investors Q VIII, L.P. 
 KBL Healthcare, L.P. 

KBL Partnership, L.P. 
 KBL Healthcare Ventures, L.P.

 Weldon Foundation 

 AMV Partners I, L.P. 

Michael Dale 
 Brian Farley 

Bruce Shook 
 Charles E. Larsen 

 Schedule of Series E Stockholders 

Polaris Venture Partners V, L.P. 
 Polaris Venture
Partners Entrepreneurs’ Fund V, L.P. 
 Polaris Venture Partners Special Founders’ Fund V, L.P. 

Polaris Venture Partners Founders’ Fund V, L.P. 

Pfizer Inc. 
 New Leaf Ventures II, L.P. 

QPIV, LLC 
 Three Arch Partners IV, L.P. 

Three Arch Associates IV, L.P. 
 Three Arch Capital,
L.P. 
 TAC Associates L.P. 
 Investor Growth
Capital Limited 
 Investor Group, L.P. 

 ONSET IV, L.P. 

InterWest Partners VIII, L.P. 
 InterWest Investors
VIII, L.P. 
 InterWest Investors Q VIII, L.P. 

Weldon Foundation 
 Michael Dale 

Brian Farley 

 Schedule of Series D Stockholders 

New Leaf Ventures II, L.P. 
 QPIV, LLC 

Three Arch Partners IV, L.P. 
 Three Arch Associates
IV, L.P. 
 Three Arch Capital, L.P. 
 TAC
Associates L.P. 
 Investor Growth Capital Limited 

Investor Group, L.P. 

 ONSET IV, L.P. 

InterWest Partners VIII, L.P. 
 InterWest Investors
VIII, L.P. 
 InterWest Investors Q VIII, L.P. 

KBL HEALTHCARE VENTURES, L.P. 
 Weldon Foundation

 Michael Dale 
 Brian E. Farley 

 Schedule of Series C Stockholders 

QPIV, LLC 
 Three Arch Partners IV, L.P. 

Three Arch Associates IV, L.P. 
 Three Arch Capital,
L.P. 
 TAC Associates L.P. 
 AMV Partners I,
L.P. 
 Investor Growth Capital Limited 

Investor Group, L.P. 
 ONSET IV, L.P. 

 InterWest Partners VIII, L.P. 

InterWest Investors VIII, L.P. 
 InterWest Investors Q
VIII, L.P. 
 KBL HEALTHCARE, L.P. 
 KBL
Partnership, L.P. 

 Schedule of Series B Stockholders 

Three Arch Partners IV, L.P. 
 Three Arch Associates
IV, L.P. 
 Three Arch Capital, L.P. 
 TAC
Associates L.P. 
 AMV Partners I, L.P. 

Investor Growth Capital Limited 
 Investor Group, L.P.

 ONSET IV, L.P. 
 InterWest Partners VIII,
L.P. 
 InterWest Investors VIII, L.P. 
 InterWest
Investors Q VIII, L.P. 

 KBL HEALTHCARE, L.P. 

KBL Partnership, L.P. 

 Schedule of Series A-2 Stockholders 

Investor Growth Capital Limited 
 Investor Group, L.P.

 IGC Fund VI, L.P. 
 ONSET IV, L.P. 

InterWest Partners VIII, L.P. 
 InterWest Investors
VIII, L.P. 
 InterWest Investors Q VIII, L.P. 

KBL HEALTHCARE, L.P. 
 KBL Partnership, L.P. 

 Schedule of Series A-1 Stockholders 

Thomas D. Weldon Revocable Trust 
 Charles E. Larsen

 Norman R. Weldon 

 Schedule of Common Stockholders 

David W. Ankney 
 Debi Decker 

Brian E. Farley 
 Linda Faupel 

Mark Gelinas 
 Carolyn George 

Kevin Hahnen 
 William A. Hawkins 

Richard Hillstead 

 Katherine Lane 

Stanford Miller 
 Edward Peterson 

John Roccamo 
 Vidmantas A. Ruksys 

Joshua Salisbury 
 Stephen Shapiro 

Gregory Toso 
 Roelof Trip 

Steven Waite 

 Laura Wilson 

Gordon Wyatt 
 Matthew Benoit 

Jaime Binder 
 Paul Boatman 

James Breidenstein 
 Brian Chugg 

Jessica Cowherd 
 Gregory DeNardo 

David DePiro 
 Heather Elrod 

 Jonathan Fitzgerald 

Amy Garraty 
 Kathleen Garstka 

Matthew Gelfman 
 Evelyn Gittinger 

Todd Goldberg 
 David Hartman 

Holly Hayes 
 Rosemary Healy 

Paul Holman 
 Steven P. Iskenderian 

 Jonathan Law 

Laura Leonard 
 William Leonhard 

Ashley Linn 
 Christopher Martin 

Michael Miller 
 Christopher Morra 

Greg Morris 
 Sara Mueller 

Deborah Mulligan 
 Michael Ogar 

 Joy Paterno 

Suzanne Prescott 
 Daniel Puskas 

Ann Rossi 
 Eric Roux 

Alyssa Schwartz 
 Stacey Scoma 

Robert Shek 
 Ellen Smith 

Shanen Taylor 
 Sara Thompson 

 Kim Tietz 
 Mark
Williams 
 Cynthia Zajac 

 Schedule of Key Officers 

Chris Thatcher 
 Bruce Shook 

Mark Bausinger 
 Mark Demitrack, MD 

Mark Riehl 
 Judy Ways, Ph.D. 

James Breidenstein 
 Mary K. Hailey 

Suzanne McMonigle 
 Steve MacKinnnon 

Stanford W. Miller 

 Peter Donato 

 EXHIBIT A to Sixth Amended and Restated Stockholders’ Agreement 

Neuronetics, Inc. 

Instrument of Adherence 
 Reference
is made to that certain Sixth Amended and Restated Stockholders’ Agreement, dated as of June 1, 2017, a copy of which is attached hereto (as amended and in effect from time to time, the “Stockholders’ Agreement”), by
and among Neuronetics, Inc., a Delaware corporation (the “Company”), and the Stockholders party thereto. Capitalized terms used herein without definition shall have the respective meanings ascribed thereto in the Stockholders’
Agreement. 
 The undersigned,                     , in
order to become the owner or holder of                      shares [or options, warrants, or other rights to purchase such shares] (the
“Acquired Shares”) of [Common Stock/Preferred Stock] of the Company, hereby agrees that, from and after the date hereof, (i) the undersigned has become [an Additional Stockholder][a Key Officer] party to the Stockholders’
Agreement as a [Common Stockholder/Series A-1 Holder/Series A-2 Holder/Series B Holder/Series C Holder/Series D Holder/Series E Holder/Series F Holder/Series G
Holder/Key Officer] party thereunder and is entitled to all of the benefits under and is subject to all of the obligations, restrictions and limitations set forth in the Stockholders’ Agreement that are applicable to the [Common
Stockholders/Series A-1 Holders/Series A-2 Holders/Series B Holders/Series C Holders/Series D Holders/Series E Holders/Series F Holders/Series G Holders/Key Officers],
(ii) all of the Acquired Shares are entitled to all of the benefits, and are subject to all of the obligations, restrictions, limitations, provisions and conditions, under the Stockholders’ Agreement that are applicable to the Shares held by
the undersigned, if any, (iii) the Stockholders party to the Stockholders’ Agreement are intended third-party beneficiaries of this Instrument of Adherence, and (iv) any notice required to be given to the Company pursuant to
Section 10.2 of the Stockholders’ Agreement should be sent to Neuronetics, Inc., 3222 Phoenixville Pike, Malvern, Pennsylvania 19355. This Instrument of Adherence shall take effect and shall become a part of the Stockholders’
Agreement immediately upon execution. 
 Executed as of the date set forth below. 

Signature:                  
                           

Name:                   
                          

Address:                   
                          
  

                    
                         
  

                    
                         

Tel.
No.:                                        
     
 Fax
No.:                                        
     

E-mail:                   
                            

Date:                   
                               

 Acknowledged and Accepted: 
  

			
	NEURONETICS, INC.
		
	By:	 	                                     
                                   
		 	Name:
		 	Title:

 EXHIBIT B to Sixth Amended and Restated Stockholders’ Agreement 

Consent of Spouse 

I, [                    ], spouse of
[                    ], acknowledge that I have read the Sixth Amended and Restated Stockholders’ Agreement, dated as of June 1, 2017, to
which this Consent is attached as Exhibit B (the “Agreement”), and that I know the contents of the Agreement. I am aware that the Agreement contains provisions regarding (i) voting and transfer of shares of capital
stock, and/or (ii) certain rights to certain other holders of capital stock of the Company upon a proposed Transfer of Offered Securities of the Company which my spouse may own including any interest I might have therein. 

I hereby agree that my interest, if any, in any Offered Securities of the Company subject to the Agreement shall be irrevocably bound by the
Agreement and further understand and agree that any community property interest I may have in such Offered Securities of the Company shall be similarly bound by the Agreement. 

I am aware that the legal, financial and related matters contained in the Agreement are complex and that I am free to seek independent
professional guidance or counsel with respect to this Consent. I have either sought such guidance or counsel or determined after reviewing the Agreement carefully that I will waive such right. 

Dated as of the [    ] day of [            ,
        ].EX-10.4

 Exhibit 10.4 

EMPLOYMENT AGREEMENT 

THIS EMPLOYMENT AGREEMENT (the “Agreement”), dated as of November 1, 2014, (the “Effective Date”) is
made and entered into by and between Neuronetics, Inc., a Delaware corporation (the “Company”), and Christopher Thatcher (the “Executive”). 

WHEREAS, the Company desires to employ Executive as the Company’s President and Chief Executive Officer on at at-will basis, and the Executives wishes to enter into such employment with the Company on at-will basis, on the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreement contained herein and intending to be bound hereby, the
parties agree as follows: 
 1. Duration of Agreement. The “Effective Date” of this Agreement shall mean a mutually-agreed
date (not later than December 31, 2014) following the Executive’s receipt of notice from the Company that the Company (i) has entered into a convertible subordinated debt financing of at least Ten Million Dollars ($10,000,000) and up
to Twenty-Five Million Dollars ($25,000,000) with one or more investors on substantially the same terms and has received initial proceeds of at least Nine Million Dollars ($9,000,000) at a closing to occur in November 2014 and a final closing to
occur no later than March 31, 2016 (the “Initial Financing”); and (ii) has executed a binding letter of intent with Oxford Finance LLC (“Oxford”) providing for, among other things, revised terms of affirmative and
negative covenants in connection with that certain lending facility, between the Company and Oxford. Unless terminated or amended in writing by the parties, this Agreement will govern the Executive’s continued employment by the Company until
that employment ceases in accordance with Section 5 hereof. 

  
  

 
 Executive’s Initials & Date 

 2. Position; Duties. The Executive will be employed as the Company’s President and
Chief Executive Officer, reporting directly to the Company’s Board of Directors (the “Board”). The Executive shall devote his best efforts and all of his business time and services to the Company and its Affiliates and shall have such
duties, scope of authority, and responsibilities as may be customarily incident to his position and as are more fully described in Schedule A hereto. The Company shall use its best efforts to encourage the shareholders of the Company to elect
the Executive to be a voting member of the Board at the next election of directors occurring as of the Effective Date and continuing for so long as the Executive remains employed with the Company as its President and Chief Executive Officer;
provided that, if so elected, the Executive will serve on the Board without compensation (other than the compensation set forth herein). The Executive shall not, in any capacity, engage in other business activities or perform services for any other
Person without the prior written consent of the Company; provided, however, that without such consent, the Executive may engage in charitable or public service, so long as such activities do not interfere with the Executive’s
performance of his duties and obligations hereunder. Notwithstanding the foregoing, the Executive may continue to serve on the board of directors of MicroInterventional Devices until such time as the Board determines in good faith that the
Executive’s service on such board presents a conflict of interest and/or is interfering with the Executive’s performance of his duties and obligations hereunder. 

3. Place of Performance. The Executive will perform his services hereunder at the principal executive offices of the Company in
Malvern, Pennsylvania; provided, however, that the Executive may be required to travel from time to time for business purposes. 

  
  

Executive’s Initials & Date 
 -2- 

 4. Compensation and Indemnification. 

4.1. Base Salary. The Executive’s annual base salary will be $370,000.00 (the “Base Salary”), which shall be paid
ratably by the Company to the Executive each month in accordance with the Company’s payroll practices as in effect from time to time. The Base Salary shall be reviewed on an annual basis following the 2015 calendar year and may be increased
(but not decreased) by the Board, with any such increase taking effect as of the first day of the applicable calendar year. 
 4.2. Start
Date Bonuses. 
 4.2.1. The Company shall pay to the Executive a “Start Date Bonus” in cash (less applicable withholding tax)
equal to $140,000.00 (less applicable withholding tax) (the “Start Date Bonus”), payable as follows: (i) $80,000 (less applicable withholding tax) within ten (10) business days following the Effective Date (the “First
Installment Payment”); and (ii) $60,000 (less applicable withholding tax) on or before August 1, 2015 (the “Second Installment Payment”); provided the Executive remains continuously and actively employed with the Company through
each such payment date. 
 4.2.2. Notwithstanding the foregoing, the Executive shall repay within ninety (90) business days following
the applicable employment cessation date: (i) the First Installment Payment if the Executive ceases to be actively employed with the Company prior to the first (1st) anniversary of the
Effective Date for any reason other than a termination of employment by the Company without Cause (as defined below) or a resignation by the Executive for Good Reason (as defined below); and (ii) the Second Installment Payment if the Executive
ceases to be actively employed with the Company prior to February 1, 2016 for any reason other than a termination of employment by the Company without Cause or a resignation by the Executive for Good Reason. 

  
  

Executive’s Initials & Date 
 -3- 

 4.3. Annual Bonuses. 

4.3.1. For each full calendar year of his employment hereunder (beginning with the 2015 calendar year), the Executive will be eligible to earn
an annual bonus. The target amount of that bonus will be forty percent (40%) of the Executive’s Base Salary for the applicable calendar year (the “Target Bonus”). The actual bonus payable with respect to a particular year will
be determined by the Board, based on the achievement of corporate and/or individual performance objectives (the “Performance Objectives”) mutually determined and agreed to by the Board and the Executive. The Performance Objectives
for 2015 shall be established on a date no earlier than 90 days and no later than 120 days following the date of this Agreement by the Executive and the Board. Each year during the Executive’s employment, the Performance Objectives for the
following year shall be reviewed on a calendar year basis no later than fifteen (15) days prior to the end of such calendar year. Any bonus shall be paid no later than seventy-five (75) days following the end of each calendar year for
which the bonus is determined and awarded by the Board. 
 4.3.2. For purposes of determining any bonus payable to Executive, the
measurement of achievement of the Performance Objectives with respect to that particular year will be performed by the Board in good faith. From time to time, the Board may, in its sole discretion, make adjustments to the method of measurement of
Performance Goals so that required departures from the Company’s operating budget, changes in accounting principles, 

  
  

Executive’s Initials & Date 
 -4- 

 
acquisitions, dispositions, mergers, consolidations and other corporate transactions, and other factors influencing the achievement or calculation of such Performance Objectives do not affect the
operation of this Section 4.3 in a manner inconsistent with its intended purposes which, for the sake of clarity, is to evaluate and determine Executive’s annual bonus award, (which the parties acknowledge is a
significant element of Executive’s annual compensation), in accordance with agreed upon operational Performance Objectives and incent achievement of those Performance Objectives. 

4.4. Change in Control Bonus. 

4.4.1. In addition to the compensation described in the other paragraphs of this Section 4 and in Section 5, and the Company’s
Change In Control Carve Out Plan (the “Carve Out Plan”) upon the first occurrence of a Change in Control, the Company shall pay to the Executive a cash lump sum payment (less applicable withholding tax) equal to forty percent (40%) of his
then Base Salary (the “Change in Control Bonus”), provided the Executive remains continuously and actively employed with the Company through the date of such Change in Control. The Change in Control Bonus will be paid to the
Executive as soon as administratively feasible following, but in no event later than sixty (60 days) following, the Change in Control. 

4.4.2. For purposes of this Agreement, “Change of Control” with respect to the Company, shall have the meaning set forth in
the Company’s Change In Control Carve-out Plan, dated July 18, 2014. 

  
  

Executive’s Initials & Date 
 -5- 

 4.5. Equity Compensation. 

4.5.1. Initial Grant. As soon as practicable after the effective date of this Agreement and subject to Board and all other required
approvals, the Company shall grant to the Executive under the Company’s Amended and Restated 2003 Stock Incentive Plan (the “Plan”) a non-qualified stock option to purchase a number of
shares of the common stock of the Company equal to 5.15% of the Company’s fully-diluted common stock (excluding the effects of any conversion of the (i) debt issued in connection with the Initial Financing, (ii) the investor
convertible subordinated debt issued in January 2014 or (iii) any other convertible debt that is issued prior to the thirty-six (36) month anniversary of the Effective Date) with a per share exercise
price equal to the fair market value of the Company’s common stock (as determined by the Board pursuant to the Plan) at the time of grant. The Initial Grant shall be granted pursuant to and governed by the terms of a stock option award
agreement in a form provided by the Company at the time of grant; provided, however, that the form shall provide for cashless exercise of the option in an amount sufficient to satisfy the option exercise price. Provided the Executive remains
continuously and actively employed with the Company through the applicable vesting date, the Initial Grant will be vested and exercisable with respect to (i) 10% of the underlying common stock as of the Effective Date, (ii) 25% of the underlying
common stock on the first (1st) anniversary of the Effective Date, and (iii) the remaining shares of underlying common stock in substantially equal monthly installments over the 36-month period that commences on the first (1st) anniversary of the Effective Date. Notwithstanding the foregoing, the Initial Grant shall be fully vested and
exercisable immediately prior to, but contingent upon, the occurrence of a Change in Control (as defined above), provided the Executive remains continuously and actively employed with the Company through the date of such Change in Control. 

  
  

Executive’s Initials & Date 
 -6- 

 4.5.2. Additional Grant(s). As soon as practicable after the closing of one or more
issuances of equity in bona fide equity financings by the Company that are closed subsequent to the Initial Financing and prior to the thirty-six (36) month period after the Effective Date (the
“Additional Financing”), the Company shall grant to the Executive a nonqualified stock option to purchase a number of shares of the Company’s common stock sufficient to cause the total amount such shares issued or issuable to the
Executive upon full vesting and exercise of his Company stock options to equal 5.15% of the Company’s fully-diluted common stock (excluding the effects of any conversion of the (i) debt issued at the Initial Financing, (ii) the
investor convertible subordinated debt issued in January 2014 or (iii) any other convertible debt that is issued prior to the thirty-six (36) month anniversary of the Effective Date) when taking into
account the Initial Grant and this Additional Grant, provided that the Executive remains continuously and actively employed with the Company through the date that the Additional Grant is made. The Additional Grant shall have a per share exercise
price equal to the fair market value of the Company’s common stock (as determined by the Board pursuant to the Plan) at the time of grant and be subject to the same vesting conditions as applicable to the Initial Grant. Notwithstanding the
foregoing, the Additional Grant shall not be augmented by or apply to any portion of the Additional Financing in excess of Twenty Five Million Dollars ($25,000,000), provided, however, that such limitation shall not affect the increase in the
Additional Grant to Executive in connection with the conversion of the convertible debt issued in the Initial Financing. For the avoidance of doubt, (i) a conversion of the convertible 

  
  

Executive’s Initials & Date 
 -7- 

 
subordinated debt issued in the Initial Financing into preferred or common stock, (ii) a conversion of the convertible subordinated debt issued by the Company in January 2014 into preferred
or common stock, or (iii) the conversion, of any other convertible debt that is issued prior to the thirty-six (36) month anniversary of the Effective Date, in each such instance after such thirty-six (36) month period, shall be deemed to occur within such thirty-six (36) month period (prior to the Additional Financing) and will result in similar
additional grants to the Executive at the time of such conversion(s), provided that the Executive remains continuously and actively employed with the Company through the date(s) that each actual additional grant is made. 

4.6. Employee Benefits. The Executive will be eligible to participate in the employee benefit plans, policies or arrangements
maintained by the Company for its employees generally, subject to the terms and conditions of such plans, policies or arrangements; provided, however, that this Agreement will not limit the Company’s ability to amend, modify or
terminate such plans, policies or arrangements at any time for any reason. Without limiting the generality of the foregoing, the Executive will be eligible to participate in the Carve-Out Plan following its
adoption by the Board. 
 4.7. Paid Time Off. The Executive will be eligible for four (4) weeks paid time off and national
holidays in accordance with the Company’s policy, as may be amended from time to time. 
 4.8. Reimbursement of Expenses. The
Company will pay or reimburse the Executive for all reasonable business expenses incurred or paid by the Executive in the performance of his duties and responsibilities for the Company in accordance with the expense reimbursement policies of the
Company, as may be amended from time to time. 

  
  

Executive’s Initials & Date 
 -8- 

 4.9. D&O Coverage. The Company shall maintain directors and officers liability
insurance coverage for Executive with coverage and limits which are reasonable and customary for an entity similarly-situated to the Company. 

4.10. Indemnification. The Company acknowledges and agrees that Executive shall be indemnified and held harmless from and against any
and all claims or liabilities, or threatened claims or liabilities, by reason of his employment as an employee, officer or director of the Company and its affiliates to the fullest extent permitted under applicable law, the Company’s corporate
governance documents, including providing Executive with prompt advancement of reasonable fees, costs and expenses of counsel or other professionals of his choice incurred in respect thereof or pursuant to any applicable insurance policy maintained
by the Company from time to time for its employees, officers and directors. 
 5. Termination; Severance. The Executive’s
employment hereunder shall terminate on the earliest of: (i) on the date set forth in a written notice from the Board that his employment with the Company has been or will be terminated, (ii) on the a date not less than thirty-days
following written notice from the Executive that he is resigning from the Company, (iii) on the date of his death or (iv) on the date of his Disability, as determined in accordance with Section 7.5. Upon cessation of his employment
for any reason, unless otherwise consented to in writing by the Board, the Executive shall resign immediately from any and all officer, director and other positions he then holds with the Company and/or its Affiliates. Upon any cessation of his
employment with the Company, the Executive will be entitled only to such compensation and benefits as described in this Section 5. 

  
  

Executive’s Initials & Date 
 -9- 

 5.1. Termination without Cause or Resignation for Good Reason. If the Executive’s
employment by the Company ceases due to a termination by the Company without Cause (as defined below) or a resignation by the Executive for Good Reason (as defined below), the Company shall: 

5.1.1. pay to the Executive all accrued and unpaid Base Salary (at the annual rate then in effect) and vacation accrued through the date of
such cessation of employment at the time such Base Salary would otherwise be paid according to the Company’s usual payroll practices; 

5.1.2. to the extent then unpaid, pay to the Executive the annual bonus (if any) with respect to the calendar year ended immediately prior to
the cessation of the Executive’s employment, which such bonus shall be paid at the time such bonus would have otherwise been paid absent the Executive’s cessation of employment but in no event later than the last day of the year in which
the Executive’s employment ceases; 
 5.1.3. pay to the Executive a pro-rated bonus for the
calendar year in which such termination occurs, which proration shall be determined by multiplying (i) the quotient obtained by dividing (A) the number of days the Executive worked in the calendar year his employment with the Company
ceases by (B) 365, and (ii) his Target Bonus, which such bonus shall be paid at the time such bonus would have otherwise been paid absent the Executive’s cessation of employment; 

  
  

Executive’s Initials & Date 
 -10- 

 5.1.4. pay to the Executive monthly severance payments equal to
one-twelfth of the Executive’s then current Base Salary for a period (the “Severance Period”) equal to: (i) twelve (12) months, if such termination of employment occurs on or prior
to the second 2nd anniversary of the Effective Date, or (ii) eighteen (18) months, if such termination of employment occurs after the second
2nd anniversary of the Effective Date; 
 5.1.5. if the Executive validly elects to
receive continuation coverage under the Company’s group health plan pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), reimburse the Executive the applicable premium otherwise payable for such
COBRA continuation coverage for the Severance Period; and 
 5.1.6. cause any then vested stock options held by the Executive as of
immediately prior to the effective date of such termination of employment to remain exercisable until the earlier to occur of (i) the first (1st) anniversary of the effective date of such
termination of employment or (ii) the expiration date of the stock option. 
 Except as otherwise provided in this
Section 5.1, and, if applicable, Section 4.4.1 (Change In Control Bonus) and the Carve Out Plan, all compensation and benefits will cease at the time of the Executive’s cessation of employment and the Company will
have no further liability or obligation by reason of such cessation of employment. The payments and benefits described in this Section 5.1 are in lieu of, and not in addition to, any other severance arrangement maintained

  
  

Executive’s Initials & Date 
 -11- 

 
by the Company. Notwithstanding any provision of this Agreement, except Section 4.4.1 and the Carve Out Plan, if applicable, the payments and benefits described in
Section 5.1.2 through Section 5.1.6 are conditioned on: (a) the Executive’s execution and delivery to the Company and the expiration of all applicable statutory revocation periods, by the
60th day following the effective date of his cessation of employment, of a severance agreement that includes a mutual general release and waiver of claims by each party against the other and a
mutual non-disparagement provision substantially in a form reasonably acceptable to the Company (the “Release”); and (b) the Executive’s continued compliance with the provisions of
the Restrictive Covenant Agreement (as defined below). Subject to Section 5.4, below, the benefits described in Sections 5.1.4 and 5.1.5 will begin to be paid or provided as soon as administratively practicable after
the Release becomes irrevocable, provided that if the 60 day period described above begins in one taxable year and ends in a second taxable year such payments or benefits shall not commence until the second taxable year. 

5.2. Other Terminations. If the Executive’s employment with the Company ceases for any reason other than as described in
Section 5.1 above (including but not limited to (a) termination by the Company for Cause, (b) resignation by the Executive without Good Reason, (c) termination as a result of the Executive’s Disability,
or (d) the Executive’s death, then the Company’s obligation to the Executive will be limited solely to (A) the payment of accrued and unpaid Base Salary (at the annual rate then in effect) and vacation through the date of such
cessation of employment and (B) if the termination is as a result of the Executive’s Disability or death, and the bonus payments provided for in Sections 5.1.2 and 5.1.3.. All compensation and benefits will cease at the time of such
cessation of employment and, except as 

  
  

Executive’s Initials & Date 
 -12- 

 
otherwise provided by COBRA, the Company will have no further liability or obligation by reason of such termination. The foregoing will not be construed to limit the Executive’s right to
payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract. 

5.3. No Mitigation; No Offset. In no event shall Executive be obligated to seek other employment or take any other action by way of
mitigation of the amounts payable to and benefits provided to him under any of the provisions of this Section 5 and, such amounts and benefits shall not be reduced whether or not he obtains other employment. 

5.4. Compliance with Section 409A. Notwithstanding anything to the contrary in this Agreement, no portion of the
benefits or payments to be made under Section 5.1.2 through Section 5.1.6 hereof will be payable until the Executive has a “separation from service” from the Company within the meaning of
Section 409A of the Code. In addition, to the extent compliance with the requirements of Treas. Reg. § 1.409A-3(i)(2) (or any successor provision) is necessary to avoid the application of an
additional tax under Section 409A of the Code to payments due to the Executive upon or following his “separation from service”, then notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy,
agreement or arrangement), any such payments that are otherwise due within six months following the Executive’s “separation from service” (taking into account the preceding sentence of this paragraph) will be deferred without interest
and paid to the Executive in a lump sum immediately following that six month period. This paragraph should not be construed to prevent 

  
  

Executive’s Initials & Date 
 -13- 

 
the application of Treas. Reg. § 1.409A-1(b)(9)(iii) (or any successor provision) to amounts payable hereunder. For purposes of the application of
Section 409A of the Code, each payment in a series of payments will be deemed a separate payment. 
 6. Restrictive Covenants.
The Executive acknowledges and agrees to abide by the terms of, and agrees that his employment by the Company is contingent upon his valid and binding execution of the Confidentiality, Non-Competition and
Inventions Assignment Agreement attached hereto as Exhibit B (the “Restrictive Covenant Agreement”). The Executive acknowledges that the terms of the Restrictive Covenant Agreement shall continue to remain in full-force and
effect following the cessation of the Executive’s employment with the Company for any reason. If the Executive does not execute the Restrictive Covenant Agreement on or before the fifth (5th)
calendar day following the date of this Agreement, the Company’s obligations under this Agreement shall be null and void ab initio. 

7. Certain Definitions. For purposes of this Agreement: 

7.1. “Affiliate” means, with respect to any specified Person, any other Person that directly or indirectly, through one or
more intermediaries, Controls, is Controlled by, or is under common Control with, such specified Person, provided that, in any event, any business in which the Company has any direct ownership interest shall be treated as an Affiliate of the
Company. 
 7.2. “Cause” means (i) indictment, conviction, or the entry of a plea of guilty or no contest to,
(A) a felony or (B) a misdemeanor (other than a DUI or similar crime) involving 

  
  

Executive’s Initials & Date 
 -14- 

 
moral turpitude, or that causes material damage to the Company’s public image or reputation, or causes material harm to the Company’s operations or financial performance,
(ii) gross negligence or willful misconduct with respect to his duties and responsibilities to the Company, including, without limitation, commission of any act of proven fraud, embezzlement, or theft in the course of his employment, after a
reasonable and good faith investigation by the Board; (iii) alcohol abuse or illegal use of controlled substances (other than prescription drugs taken in accordance with a physician’s prescription) in the event the Company has reasonable
grounds for suspecting that he is under the influence of illegal drugs or alcohol while at work and his ability to perform his duties and responsibilities has been materially impaired; (iv) willful refusal or failure to perform any specific
material lawful direction received by the Board (other than due to a physical or mental illness or Disability), which failure or refusal is not cured within 30 days after delivery of written notice from the Company thereof; (v) the failure to
timely execute the Restrictive Covenant Agreement in a manner consistent with Section 6; (vi) willful and material breach of any written agreement with or duty owed to the Company (including this Agreement or any
breach of the Restrictive Covenant Agreement); or (vii) the Company determines that the Executive intentionally omitted any requested information or falsified any disclosed information either in the Executive’s resume or during the
Executive’s interview process with the Company. 
 7.3. “Code” means the Internal Revenue Code of 1986, as amended.

 7.4. “Control” (including, with correlative meanings, the terms “Controlled by” and “under common Control
with”), as used with respect to any Person, means the direct or indirect possession of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership of voting securities, by contract or
otherwise. 

  
  

Executive’s Initials & Date 
 -15- 

 7.5. “Disability” means a condition entitling the Executive to benefits under
the Company’s long term disability plan, policy or arrangement; provided, however, that if no such plan, policy or arrangement is then maintained by the Company and applicable to the Executive, “Disability” will mean the
Executive’s inability to perform his duties under this Agreement due to a mental or physical condition (other than alcohol or substance abuse) that can be expected to result in death or that can be expected to last (or has already lasted) for a
continuous period of 90 days or more, or for 120 days in any 180 consecutive day period, as determined by an independent physician reasonably satisfactory to the Executive and the Company whose fees shall be paid by the Company. Termination as a
result of a Disability will not be construed as a termination by the Company “without Cause.” 
 7.6. “Fully-Diluted
Common Stock” means as of the date of measurement, the sum of (a) all outstanding shares of the Company’s common stock; (b) all outstanding shares of the Company’s preferred stock (if any) on an as-converted to common stock basis; and (c) all shares of common stock issuable pursuant to exercise or conversion of all outstanding options, warrants or convertible securities, including all shares of common
stock reserved for grant pursuant to any stock option plans. 
 7.7. “Good Reason” means any of the following, without the
Executive’s prior consent: (a) a material adverse change of the Executive’s position with the Company that reduces his title, level of authority, duties and/or responsibilities from those in effect immediately prior to

  
  

Executive’s Initials & Date 
 -16- 

 
the reduction; (b) a reduction in Base Salary or Target Bonus; (c) any failure to provide that the Executive is eligible to participate in the Company benefit plans on a basis that is:
(i) at least as favorable as those enjoyed by similarly-situated senior corporate officers of the Company or (ii) granted to the Executive by this Agreement; (d) a relocation of the Executive’s principal worksite of more than
35 miles unless such relocation reduces the Executive’s commute to such worksite; or (e) any material breach of this Agreement by the Company. However, none of the foregoing events or conditions will constitute Good Reason unless the
Executive provides the Company with written objection to the event or condition within 60 days following the occurrence thereof, the Company does not reverse or otherwise cure the event or condition within 30 days of receiving that written
objection, and the Executive resigns his employment within 30 days following the expiration of that cure period. 
 7.8.
“Person” means any individual, firm, corporation, partnership, limited liability company, trust, joint venture, association, governmental entity, unincorporated entity or other entity. 

8. Miscellaneous. 
 8.1.
Cooperation. The Executive further agrees that, subject to prompt reimbursement of his reasonable expenses, including reasonable attorneys’ fees for counsel of his choice if reasonably necessary to protect his interests, he will
cooperate fully with the Company and its counsel with respect to any matter (including litigation, investigations, or governmental proceedings) in which the Executive was in any way involved during his employment with the Company. The Executive
shall render such cooperation in a timely manner 

  
  

Executive’s Initials & Date 
 -17- 

 
on reasonable notice from the Company, so long as the Company exercises commercially reasonable efforts to schedule and limit its need for the Executive’s cooperation under this paragraph so
as not to interfere with the Executive’s other personal and professional commitments. This Section 8.1 shall not be considered a waiver of Executive’s right to refuse to provide testimony or information or assistance based on
“Fifth Amendment” grounds. 
 8.2. Section 409A. 

8.2.1. Notwithstanding anything herein to the contrary or otherwise, except to the extent any expense, reimbursement or in-kind benefit provided to the Executive does not constitute a “deferral of compensation” within the meaning of Section 409A of the Code, and its implementing regulations and guidance, (i) the
amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive in any other calendar year, (ii) the reimbursements for expenses for which the Executive is entitled to be reimbursed shall be made on or before the last day of the
calendar year following the calendar year in which the applicable expense is incurred and (iii) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for
any other benefit. 
 8.2.2. Anything to the contrary herein notwithstanding, all benefits or payments provided by the Company to the
Executive that would be deemed to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code are intended to comply with Section 409A of the Code. Notwithstanding anything in this Agreement to
the contrary, distributions may only be made under this Agreement upon an event and in a manner permitted by Section 409A of the Code or an applicable exemption. 

  
  

Executive’s Initials & Date 
 -18- 

 8.3. Section 280G. 

8.3.1. Notwithstanding any other provision of this Agreement, if any payment or benefit due under this Agreement, together with all other
payments and benefits that the Executive receives or is entitled to receive from the Company or any of its subsidiaries, Affiliates or related entities, will constitute an “excess parachute payment” (as that term is defined in
Section 280G(b)(1) of the Code and related regulations), such payments and benefits will be limited to the minimum extent necessary to ensure that no portion thereof will fail to be tax-deductible to the
Company or its Affiliates by reason of Section 280G of the Code. If a reduction to the payments or benefits otherwise payable under this Agreement is required pursuant to this Section 8.3, such reduction shall occur to
the payments or benefits in the order that results in the greatest economic present value of all payments actually made to the Executive. 

8.3.2. Notwithstanding the foregoing and provided that no securities of the Company, any member of its affiliated group (within the meaning
of Section 1504 of the Code) and any entity possessing a direct or indirect ownership interest in the Company which interest constitutes more than 1/3 of such entity’s gross fair market value (as described in Treasury Regulation Section 1.280G-1, Q&A 6) are then publicly traded, to the extent that any payments and/or benefits provided to the Executive from the Company or any of its subsidiaries, Affiliates or related entities, will
constitute an “excess parachute payment” (as that term is 

  
  

Executive’s Initials & Date 
 -19- 

 
defined in Section 280G(b)(1) of the Code and related regulations) without regard to the application of Section 8.3.1, the Company agrees to submit such payments
and/or benefits for approval by the holders of more than 75% of the voting power of the outstanding equity securities of the Company in a manner intended to comply with Section 280G(b)(5)(B) of the Code and regulations thereunder. The Executive
acknowledges that to the extent any such payment and/or benefits are submitted to the Company’s equity holders for approval pursuant to the preceding sentence, the Company’s equity holders have no obligation to approve such payments and/or
benefits (or portions thereof) and that if such approval is not timely obtained in a manner that satisfies Section 280G(b)(5)(B) of the Code and regulations thereunder, such payments or benefits (to the extent necessary to avoid the
Company’s loss of deduction pursuant to Section 280G of the Code) will be reduced in accordance with Section 8.3.1 hereof. 

8.4. Other Agreements. The Executive represents and warrants to the Company that there are no restrictions, agreements or
understandings whatsoever to which he is a party that would prevent or make unlawful his execution of this Agreement, that would be inconsistent or in conflict with this Agreement or the Executive’s obligations hereunder, or that would
otherwise prevent, limit or impair the performance by the Executive of his duties under this Agreement. 
 8.5. Dispute Resolution.

 8.5.1. Mediation. Prior to instituting any arbitration as provided in Section 8.5.2, the parties shall meet in good faith and
attempt to resolve any dispute arising from or relating to this Agreement, the Restrictive Covenant Agreement, the Carve-Out Plan, the Plan 

  
  

Executive’s Initials & Date 
 -20- 

 
or the employment relationship through non-binding mediation. One (1) individual who is mutually acceptable to the parties shall be appointed as
mediator, provided that the mediator shall be experienced in mediation of employment contract disputes. The mediator’s fees and costs, as well as the costs of holding and conducting the mediation, shall be divided equally between the parties.
Each party shall pay its portion of the anticipated fees and costs at least ten (10) business days in advance of the mediation. Each party shall pay its own attorney fees, costs, and individual expenses associated with conducting and attending
the mediation. Mediation shall be held in Wilmington, Delaware and shall last no more than two (2) business days. 
 8.5.2.
Arbitration. If mediation is unsuccessful, any controversy or claim arising out of or relating to the Agreement, the Restrictive Covenant Agreement, the Carve-Out Plan, the Plan or the breach thereof,
shall be resolved by arbitration administered by the American Arbitration Association under its then Expedited Procedures of Employment Arbitration Rules, and judgment on the award rendered by the arbitrator may be entered in any court having
jurisdiction thereof. The Executive waives all rights to trial by jury or by any court. Claims made and remedies sought as part of a class action, private attorney general or other representative action (hereafter all included in the term
“class action”) are subject to arbitration on an individual basis, not on a class or representative basis. No class actions, joinder or consolidation of any claim with a claim of any other person or entity shall be allowable in
arbitration, without the written consent of both the Executive and the Company. 
 THE EXECUTIVE WAIVES ALL RIGHTS TO TRIAL BY JURY OR BY ANY COURT. IF
THE EXECUTIVE FILES A CLAIM OR COUNTERCLAIM AGAINST THE COMPANY, HE MAY ONLY DO SO ON AN INDIVIDUAL BASIS AND NOT WITH ANY OTHER EMPLOYEE OR AS PART OF A CLASS OR CONSOLIDATED ACTION. 

  
  

Executive’s Initials & Date 
 -21- 

 All arbitration proceedings shall be held in Wilmington, Delaware, unless the laws of the state in which the
Executive resides expressly require the application of its laws, in which case the arbitration shall be held in the capital of that state. There shall be one (1) arbitrator, an attorney at law, who shall have expertise in business law with a
strong preference being an attorney knowledgeable in the medical device business, selected from the panel which the American Arbitration Association provides. In deciding any dispute, the arbitrator shall be required to (i) apply the terms and
conditions of this Agreement to such dispute; (ii) set forth in writing the award and a summary of those facts considered by the arbitrator to be material to the decision; and (iii) allocate in the arbitrator’s discretion, between the
parties, all costs of the arbitration, including facility fees and the fees and expenses of the arbitrator and reasonable attorneys’ fees, costs and expert witness fees of the Parties. The decision of the arbitrator shall be final and binding
on the parties and may, if necessary, be reduced to a judgment in any court of competent jurisdiction. This agreement to arbitration shall survive any termination or expiration of the Agreement. 

8.6. Successors and Assigns. The Company may assign this Agreement to any Affiliate or to any successor to its assets and business by
means of liquidation, dissolution, sale of assets or otherwise. For avoidance of doubt, a termination of the Executive’s employment by the Company in connection with a permitted assignment of the Company’s rights and obligations under this
Agreement is not a termination “without Cause” so long as the assignee offers employment to the Executive on the terms herein specified (without regard to whether the Executive accepts employment with the assignee). The duties of the
Executive hereunder are personal to Executive and may not be assigned by him. 

  
  

Executive’s Initials & Date 
 -22- 

 8.7. Governing Law and Enforcement. This Agreement will be governed by and construed in
accordance with the laws of the State of Delaware, without regard to the principles of conflicts of laws. 
 8.8. Waivers. The waiver
by either party of any right hereunder or of any breach by the other party will not be deemed a waiver of any other right hereunder or of any other breach by the other party. No waiver will be deemed to have occurred unless set forth in a writing.
No waiver will constitute a continuing waiver unless specifically stated, and any waiver will operate only as to the specific term or condition waived. 

8.9. Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid
under applicable law. However, if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provision, and this Agreement will be
reformed, construed and enforced as though the invalid, illegal or unenforceable provision had never been herein contained. 
 8.10.
Survival. This Agreement will survive the cessation of the Executive’s employment to the extent necessary to fulfill the purposes and intent of this Agreement. 

8.11. Notices. Any notice or communication required or permitted under this Agreement will be made in writing and (a) sent by
overnight courier, (b) mailed by overnight 

  
  

Executive’s Initials & Date 
 -23- 

 
U.S. express mail, return receipt requested or (c) sent by telecopier. Any notice or communication to the Executive will be sent to the address contained in his personnel file. Any notice or
communication to the Company will be sent to the Company’s principal executive offices, to the attention of its Board Chairman. Notwithstanding the foregoing, either party may change the address for notices or communications hereunder by
providing written notice to the other in the manner specified in this paragraph. 
 8.12. Legal Expenses. Upon presentment to the
Company within ninety (90) days following the Effective Date of evidence of payment (in a form reasonably acceptable to the Company), the Company shall promptly reimburse the Executive up to a maximum of $15,000 for reasonable expenses he
incurred in connection with the process of becoming employed with the Company hereunder. 
 8.13. Entire Agreement; Amendments. This
Agreement contains the entire agreement and understanding of the parties hereto relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature relating to
that subject matter, including, without limitation, the employment agreement term sheet dated [●], 2014 entered into by the Executive and the Company. This Agreement may not be changed or modified, except by an agreement in writing signed
by each of the parties hereto. 
 8.14. Withholding. All payments (or transfers of property) to the Executive will be subject to tax
withholding to the extent required by applicable law. 

  
  

Executive’s Initials & Date 
 -24- 

 8.15. Section Headings. The headings of sections and paragraphs of this Agreement are
inserted for convenience only and will not in any way affect the meaning or construction of any provision of this Agreement. 
 8.16.
Counterparts; Facsimile. This Agreement may be executed in multiple counterparts (including by facsimile signature), each of which will be deemed to be an original, but all of which together will constitute but one and the same instrument.

 8.17 Conflict With Other Agreements. If any of the definitional provisions of the Carve Out Plan, the Plan, or the Restrictive
Covenant Agreement conflict with the provisions of this Agreement, the definitional provisions of this Agreement shall govern and prevail. 

[signature page follows] 

  
  

Executive’s Initials & Date 
 -25- 

 IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized
officer, and the Executive has executed this Agreement, in each case as of the date first above written. 
  

			
	 NEURONETICS, INC.
  

	By:	 	 /s/ Kevin Bitterman

		 	Name: Kevin Bitterman
		 	Title:
	  
 CHRISTOPHER THATCHER

	  
 /s/ Christopher
Thatcher

  
  

Executive’s Initials & Date 
 -26- 

 SCHEDULE A 

(a) Executive shall serve as Chief Executive Officer of the Company and shall, subject to the direction of the Board of Directors of the
Company (the “Board”), have such powers and perform such duties as are customarily performed by the Chief Executive Officer of a similarly situated company including, but not limited to: 

(i) Developing annual budgetary, clinical, regulatory and business strategies of the Company and managing their implementation; 

(ii) Overseeing corporate hiring and supervising the performance of management, including the authority to hire, establish or modify salaries
and bonuses after review of an annual compensation policy with the Board, and terminate the employment of all Company employees; 
 (iii)
Maintaining active communication with Board; 
 (iv) Developing and maintaining relationships with key investor base, collaboration and
development partners, customers, potential customers, media, analysts and the general public on behalf of the Company; 
 (v) Enhancing
corporate visibility through active participation in investor meetings and industry conferences; 
 (vi) Identifying and assessing new
business and product opportunities; 
 (vii) Managing and leading corporate financing activities, public relations and the Company’s
intellectual property portfolio; and 
 (viii) Election as a member of the Board. 

  
  

Executive’s Initials & Date 

 EXHIBIT A 

FORM OF RESTRICTIVE COVENANT AGREEMENT 

  

 [COMPANY LETTERHEAD] 

May 25, 2018 
 VIA
E-MAIL 
 Christopher Thatcher 

[ADDRESS] 
 Re: Amendment to Employment Agreement and Option
Awards 
 Dear Chris: 
 Reference is hereby made to
(i) the Employment Agreement dated as of November 1, 2014 (the “Employment Agreement”) by and between you and Neuronetics, Inc. (the “Company”) and (ii) the Non-Qualfied Stock Option Agreements between you and the
Company with grant dates of February 19, 2015, July 5, 2015, July 20, 2017 and March 16, 2018 (together, the “Option Awards”). 

Effective as of the date of this letter, each of the Company and you agree to amend the Employment Agreement and the Option Awards as follows: 

1.    Section 4.4 of the Employment Agreement is hereby deleted in its entirety and
re-titled “Intentionally Omitted.” 
 2.    Section 5 of the
Employment Agreement is hereby revised by amending the last paragraph thereof (immediately following Section 5.1.6) in its entirety to read as follows: 

“Notwithstanding anything in this Agreement to the contrary, in the event of a termination of employment described in this
Section 5.1 that occurs within either ninety (90) days prior to, or twelve (12) months immediately following, the occurrence of a Change of Control (as defined the Amended and Restated Neuronetics, Inc. 2003 Stock Incentive Plan), the
Executive will receive the payments and benefits described in Section 5.1 above, subject to the following modifications: 

(i)    in lieu of the bonus described in Section 5.1.3, the Executive shall receive 1.5 times his then-current Target
Annual Bonus (less applicable withholding tax) payable in eighteen (18) substantially equal monthly payments; 

(ii)    the Severance Period for purposes of Sections 5.1.4 and 5.1.5 will be eighteen (18) months in lieu of twelve
(12) months; and 
 (iii)    all unvested restricted stock, stock options and other equity incentives awarded to the
Executive by the Company after March 16, 2018 will become immediately and automatically fully vested and exercisable (as applicable). 

 Except as otherwise provided in this Section 5.1, all compensation and benefits will cease
at the time of the Executive’s cessation of employment and the Company will have no further liability or obligation by reason of such cessation of employment. The payments and benefits described in this Section 5.1 are in lieu of, and not
in addition to, any other severance arrangement maintained by the Company. Notwithstanding any provision of this Agreement, the payments and benefits described in Section 5.1.2 through Section 5.1.6 (as modified by the Change of Control
provisions of this paragraph) are conditioned on: (a) the Executive’s execution and delivery to the Company and the expiration of all applicable statutory revocation periods, by the 60th day following the effective date of his cessation of
employment, of a severance agreement that includes a mutual general release and waiver of claims by each party against the other and a mutual non-disparagement provision substantially in a form reasonably
acceptable to the Company (the “Release”); and (b) the Executive’s continued compliance with the provisions of the Restrictive Covenant Agreement (as defined below). Subject to Section 5.4, below, the benefits described in
Sections 5.1.4 and 5.1.5 will begin to be paid or provided as soon as administratively practicable after the Release becomes irrevocable, provided that if the 60 day period described above begins in one taxable year and ends in a second taxable year
such payments or benefits shall not commence until the second taxable year.” 
 3.     Each of the Option Awards is
hereby amended by revising Section 2 of each award to add the following to the end thereto: 
 “Notwithstanding the foregoing, if a
Change of Control occurs and the Optionee remains continuously in service with the Company through the closing date of that Change of Control, the Option will become fully vested and exercisable immediately prior to (and contingent on) the
occurrence of that Change of Control.” 
 4.    The Option Awards with grant dates of February 19, 2015,
July 5, 2015 and July 20, 2017 are hereby amended by revising Section 4 of each award to add the following to the end thereto: 

“Additionally, the Option may be exercised through means of a “net settlement,” whereby the Exercise Price will not be due in
cash and where the number of shares of Common Stock issued to Optionee upon such exercise will be equal to: (A) the product of (a) the number of shares of Common Stock as to which the Option is then being exercised, and (b) the
excess, if any, of (1) the then current Fair Market Value per share of Common Stock over (2) the Exercise Price, divided by (B) the then current Fair Market Value per share of Common Stock. A number of shares of Common Stock equal to
the difference between the number of shares of Common Stock as to which the Option is then being exercised and the number of shares of Common Stock actually issued to the Optionee upon such net settlement will be deemed to have been withheld by the
Company in satisfaction of the applicable Exercise Price.” 
 All terms of the Employment Agreement and the Option Awards, except as expressly modified
by this letter agreement, are hereby acknowledged and ratified. 

  
 -2- 

 If you are in agreement with the terms of this letter agreement, please execute and return a fully executed copy
of this letter agreement to me. 
  

			
	Sincerely,
	
	Neuronetics, Inc.

 
			
		
	By:	 	  

		
	Title:	 	  

  

	
	 Intending to be legally bound,
 agreed on
this

	25th day of May 2018:
	
	  

	
	Christopher Thatcher

  
 -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]